Estudios Datamonitor Medicina Salud
| Título | Año | precio |
|---|---|---|
CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry playersIntroduction / / China’s expanding and aging population makes the country an attractive market for manufacturers of CNS products. |
2011 | 5.700,00$ |
CNS Market Access in India: Government investment into CNS services set to stimulate market growthIntroduction / / India's growing elderly population and expanding middle class population makes the country an attractive market |
2011 | 5.700,00$ |
Epidemiology: Acute Coronary Syndrome - Now affecting primarily the oldest populationsIntroduction / / Acute coronary syndrome is made up of three subtypes: STEMI, NSTEMI, and UA. With the exception of Japan, ACS oc |
2011 | 3.800,00$ |
Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population agesIntroduction / / In 2010, Datamonitor estimates that there were 92.4 million prevalent cases of benign prostatic hyperplasia (BPH |
2011 | 5.700,00$ |
Epidemiology: Bipolar Disorders – Population growth to mean more patients with bipolar disordersIntroduction / / In this analysis, Datamonitor estimates that there were a total of 8.5 million cases of bipolar disorders in 201 |
2011 | 5.700,00$ |
Epidemiology: HIV – Antiretrovirals prevail as patient population growsIntroduction / / The number of people living with HIV in the seven major markets (the US, Japan, France, Germany, Italy, Spain, a |
2011 | 5.700,00$ |
Epidemiology: Osteopenia and Osteoporosis – On the rise as the aging population growsIntroduction / / The prevalence of hip fractures, a condition related to osteopenia and osteoporosis, increased during the latter |
2011 | 5.700,00$ |
Epidemiology: Stroke – Aging global population leads to more incident cases of strokeIntroduction / / Due to an increasing number of aging adults in the world’s population, there will be an overall increase in the |
2011 | 3.800,00$ |
E-Prescribing StrategiesIntroduction / / As healthcare expenditure spirals ever higher, public and private healthcare payers are seeking to contain costs |
2011 | 1.900,00$ |
Hot Topics in Type 2 Diabetes: Physician Perceptions of Incretin Mimetics and TZDs ¬– Physician survey provides insights into TZD, DPP-IV, and GLP-1 usageIntroduction / / Prescribing practices for the key branded non-insulin classes – TZDs, DPP-IV inhibitors, and GLP-1 agonists – va |
2011 | 5.700,00$ |
Hot Topics: Obesity – Three Complete Response Letters and one Advisory Committee meetingIntroduction / / While two developers are pressing ahead with resubmission plans, a third is disputing US regulator handling and |
2011 | 3.800,00$ |
Hot Topics: Obesity – The US FDA and cardiovascular risk analysis: the AdComm ComethIntroduction / / Datamonitor proposes that the guidelines for developing obesity therapeutics are going to be overhauled in 2012, |
2011 | 3.800,00$ |
Key Companies: Depression - Leading players must adapt to remain competitiveIntroduction / / Companies seeking success in the depression market must react to the challenges posed by generic selective serot |
2011 | 3.800,00$ |
Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovationIntroduction / / The osteoporosis market is dominated by large pharmaceutical companies that can leverage their considerable fina |
2011 | 3.800,00$ |
Merck & Co., Inc.: PharmaVitae ReportIntroduction / / This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutica |
2011 | 5.700,00$ |
Mexico: Generics and Biosimilars OverviewIntroduction / / Interchangeable generics (GIs; genéricos intercambiables) have traditionally held a small share of the Mexican m |
2011 | 1.900,00$ |
Mexico: Healthcare System and Drug Regulatory OverviewIntroduction / / While universal healthcare has yet to be accomplished in Mexico, the government believes it is achievable in 201 |
2011 | 1.900,00$ |
Mexico: Pharmaceutical Industry Infrastructure OverviewIntroduction / / Mexico is one of the most attractive pharmaceutical markets in the Latin American region. It is increasingly ali |
2011 | 1.900,00$ |
Oncology Market Access in China - Market bolstered by rising incidence and improved regulatory environmentIntroduction / / The increasing adoption of Westernized lifestyles coupled with ongoing economic development is driving up the nu |
2011 | 5.700,00$ |
Prescribing Influences: Allergic Rhinitis – Treatment tolerability remains a key differentiatorIntroduction / / Many of the top challenges in allergic rhinitis are linked to the need for disease-modifying treatment, making t |
2011 | 3.800,00$ |
Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalateIntroduction / / The failure of obesity therapies to meet US FDA safety demands has resulted in a series of negative regulatory r |
2011 | 11.400,00$ |
R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumorsIntroduction / / The breast cancer pipeline contains 156 drugs, the majority of which (68%) are targeted therapies. VEGFR remain |
2011 | 3.800,00$ |
R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet needIntroduction / / Two key events occurred in the first half of 2011: Gralise (extended-release gabapentin; Depomed) obtained US Fo |
2011 | 3.800,00$ |
R&D Trends: Non-Insulin Antidiabetics - What opportunities remain for the vast pipeline in the crowded diabetes market?Introduction / / The non-insulins antidiabetic pipeline contains nearly 200 products. Although the current treatment algorithm is |
2011 | 3.800,00$ |
R&D Trends: Rheumatoid Arthritis - Approaching an era of novel kinase inhibitorsIntroduction / / Datamonitor has identified a total of 153 products in development for rheumatoid arthritis. There is considerabl |
2011 | 3.800,00$ |
R&D Trends: Skin and soft tissue infections - MRSA threat drives R&D interest in an increasingly fragmented marketIntroduction / / Despite the widespread use of vancomycin, the market for new drugs to treat SSTIs in hospitalized patients remai |
2011 | 3.800,00$ |
Shire plc: PharmaVitae ReportIntroduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect |
2011 | 5.700,00$ |
South Korea: Healthcare System and Drug Regulatory OverviewIntroduction / / South Korea has high quality healthcare but comparatively low public financing. With high out-of-pocket costs, d |
2011 | 1.900,00$ |
South Korea: Pharmaceutical Industry Infrastructure OverviewIntroduction / / South Korea is among the top 10 new drug developers in the world. It has high quality standards and a skilled wo |
2011 | 1.900,00$ |
Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetesIntroduction / / Datamonitor surveyed 199 primary care physicians and specialists across the seven major markets (the US, Japan, |
2011 | 7.600,00$ |
Turkey: Generics and Biosimilars OverviewIntroduction / / The Turkish generics market saw sales of $3.4bn in 2010, and has a high growth potential, driven by Turkish gene |
2011 | 1.900,00$ |
Turkey: Healthcare System and Drug Regulatory OverviewIntroduction / / Turkey continues to align its drug regulatory system with that of the EU. However, the country still has some wa |
2011 | 1.900,00$ |
Turkey: Pharmaceutical Industry Infrastructure OverviewIntroduction / / Leading multinational pharmaceutical companies often only have a small presence in the Turkish market, often thr |
2011 | 1.900,00$ |
Dendreon Corporation: PharmaVitae ReportIntroduction / / This analysis examines the historical and forecast performance for Dendreon in the prescription pharmaceutical s |
2011 | 5.700,00$ |
Product Profiles: Systemic Lupus Erythematosus – Benlysta approval brings lessons and hope to marketIntroduction / / Datamonitor surveyed 108 rheumatologists in the US in the wake of Benlysta’s approval, gauging current perceptio |
2011 | 11.400,00$ |
Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovationIntroduction / / The allergic rhinitis market continues to see areas of innovation, as seen with the April 2011 FDA filing of Dym |
2011 | 11.400,00$ |
R&D Trends: Attention-Deficit Hyperactivity Disorder - Growing pipeline indicates a trend towards adjunctive and adult therapyIntroduction / / Two drugs have progressed through the pipeline representing the first two products to receive US FDA approval fo |
2011 | 3.800,00$ |
Product Profiles: Multiple Sclerosis - Gilenya raises bar for new market entrantsIntroduction / / Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival o |
2011 | 11.400,00$ |
Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needsIntroduction / / Insulin prescribing practices and physician perception of unmet needs vary widely among the seven major markets. |
2011 | 5.700,00$ |
Epidemiology: Diabetes in Australia - Despite government efforts to promote healthy lifestyles, the number of cases of diabetes in Australia is set to soarIntroduction / / The number of people with type 2 diabetes will continue to increase, presenting a huge market for diabetic drugs |
2011 | 5.700,00$ |
Product Profiles: Osteoporosis - Novel candidates offer the greatest potentialIntroduction / / Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attr |
2011 | 11.400,00$ |
R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant diseaseIntroduction / / The late-phase prostate cancer pipeline is dominated by targeted therapies, closely followed by immunotherapies. |
2011 | 3.800,00$ |
Product Profiles: Depression - Next generation vies for second-line patientsIntroduction
/
/ Patents for the current market-leading depression brands are due to expire in the major markets between 2012 a |
2011 | 11.400,00$ |
Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribersIntroduction
/
/ Datamonitor conducted a survey of neurologists to ascertain the perceived level of unmet need in Alzheimer’s d |
2011 | 3.800,00$ |
Vertex Pharmaceuticals Inc.: PharmaVitae ProfileIntroduction
/
/ This analysis examines the historical and forecast performance for Vertex in the prescription pharmaceutical s |
2011 | 5.700,00$ |
R&D Trends: Colorectal CancerIntroduction
/
/ The 113 drug colorectal cancer (CRC) pipeline is dominated by target therapies. VEGFR remains the leading targ |
2011 | 1.900,00$ |
F. Hoffmann-La Roche Ltd: PharmaVitae ProfileIntroduction
/
/ This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical se |
2011 | 5.700,00$ |
Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV marketIntroduction
/
/ HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare. |
2011 | 3.800,00$ |
Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial dataIntroduction
/
/ Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperd |
2011 | 11.400,00$ |
Pet Healthcare Market in Sweden to 2014Introduction / / This databook provides key data and information on the pet healthcare market in Sweden. This report is a compreh |
2011 | 495,00$ |
R&D Trends: Systemic Lupus Erythematosus - Benlysta’s FDA approval provides hope for disease treatment, future trial design, and other pipeline candidatesIntroduction / / There remains considerable debate over the optimum efficacy measure and clinical trial design in SLE. While the |
2011 | 3.800,00$ |
Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industryIntroduction / / A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result |
2011 | 1.900,00$ |
Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugsIntroduction / / Although the majority of HIV drug developers already offer most of their antiretrovirals under differential pric |
2011 | 1.900,00$ |
Epidemiology: Major Abdominal Surgery – A key risk factor for deep vein thrombosis and pulmonary embolismIntroduction / / In 2010, Datamonitor estimates that there were 7.4 million major abdominal surgeries in the seven major markets. |
2011 | 5.700,00$ |
Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapiesIntroduction / / Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign |
2011 | 1.900,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in BelgiumIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in BrazilIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in BulgariaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in CanadaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in ChileIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in ChinaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in ColombiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in CroatiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in DenmarkIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in EgyptIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in EstoniaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in FinlandIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in FranceIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in GermanyIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in GreeceIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Hong KongIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in HungaryIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in IndiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in IrelandIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in IsraelIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in ItalyIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in JapanIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in LatviaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in LithuaniaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in MalaysiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in MexicoIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in MoroccoIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in New ZealandIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in NigeriaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in NorwayIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in PakistanIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in PeruIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in PolandIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in PortugalIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Republic of KoreaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in RomaniaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in RussiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Saudi ArabiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SingaporeIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SlovakiaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SloveniaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in South AfricaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SpainIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SwedenIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in SwitzerlandIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in TaiwanIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the Czech RepublicIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the NetherlandsIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the PhilippinesIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the UKIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the USIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in UkraineIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in United Arab EmiratesIntroduction / Datamonitor's retail databooks are based on market value data for eight major sectors, 16 core retail distribution |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in UruguayIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in VenezuelaIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in VietnamIntroduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut |
2011 | 495,00$ |
Analgesics Market in Japan to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level dat |
2011 | 350,00$ |
Analgesics Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level |
2011 | 350,00$ |
Analgesics Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le |
2011 | 350,00$ |
Analgesics Market in Sweden to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da |
2011 | 350,00$ |
Analgesics Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and segment lev |
2011 | 350,00$ |
Analgesics Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da |
2011 | 350,00$ |
Analgesics Market in Thailand to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level |
2011 | 350,00$ |
Analgesics Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Analgesics Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market and segment |
2011 | 350,00$ |
Analgesics Market in the UK to 2014 (OTC Healthcare)Introduction / / Analgesics Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da |
2011 | 350,00$ |
Analgesics Market in the US to 2014 (OTC Healthcare)Introduction / / Analgesics Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da |
2011 | 350,00$ |
Analgesics Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Analgesics Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Analgesics Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Analgesics Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level d |
2011 | 350,00$ |
OTC Healthcare in Canada to 2014Introduction / This databook provides key data and information on the OTC healthcare market in Canada. This report is a comprehens |
2011 | 495,00$ |
Other OTC Healthcare Products Market in Japan to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market an |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for ma |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Sweden to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for mar |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Thailand to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Other OTC Healthcare Products Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for |
2011 | 350,00$ |
Other OTC Healthcare Products Market in the UK to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Other OTC Healthcare Products Market in the US to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Other OTC Healthcare Products Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resourc |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Other OTC Healthcare Products Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Topical OTC Medicines Market in Japan to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen |
2011 | 350,00$ |
Topical OTC Medicines Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Topical OTC Medicines Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Topical OTC Medicines Market in Sweden to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Topical OTC Medicines Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Topical OTC Medicines Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Topical OTC Medicines Market in Thailand to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Topical OTC Medicines Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Topical OTC Medicines Market in the UK to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Topical OTC Medicines Market in the US to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Topical OTC Medicines Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma |
2011 | 350,00$ |
Topical OTC Medicines Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Topical OTC Medicines Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm |
2011 | 350,00$ |
Traditional Medicines Market in Japan to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen |
2011 | 350,00$ |
Traditional Medicines Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Traditional Medicines Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Traditional Medicines Market in Sweden to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Traditional Medicines Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Traditional Medicines Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Traditional Medicines Market in Thailand to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Traditional Medicines Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Traditional Medicines Market in the UK to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Traditional Medicines Market in the US to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Traditional Medicines Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma |
2011 | 350,00$ |
Traditional Medicines Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Traditional Medicines Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm |
2011 | 350,00$ |
Pharmaceuticals Logistics Spending in Australia to 2014Introduction / Pharmaceuticals Logistics Spending in Australia to 2014 assesses prospects for logistics in pharmaceutical industry |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Austria to 2014Introduction / Pharmaceuticals Logistics Spending in Austria to 2014 assesses the prospects for logistics in pharmaceutical indust |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Belgium to 2014Introduction / Pharmaceuticals Logistics Spending in Belgium to 2014 assesses the prospects for logistics in pharmaceutical indust |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Brazil to 2014Introduction / Pharmaceuticals Logistics Spending in Brazil to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Canada to 2014Introduction / Pharmaceuticals Logistics Spending in Canada to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in China to 2014Introduction / Pharmaceuticals Logistics Spending in China to 2014 assesses prospects for logistics in pharmaceutical industry. It |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in France to 2014Introduction / Pharmaceuticals Logistics Spending in France to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Germany to 2014Introduction / Pharmaceuticals Logistics Spending in Germany to 2014 assesses the prospects for logistics in pharmaceutical indust |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Hungary to 2014Introduction / Pharmaceuticals Logistics Spending in Hungary to 2014 assesses the prospects for logistics in pharmaceutical indust |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in India to 2014Introduction / Pharmaceuticals Logistics Spending in India to 2014 assesses prospects for logistics in pharmaceutical industry. It |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Italy to 2014Introduction / Pharmaceuticals Logistics Spending in Italy to 2014 assesses the prospects for logistics in pharmaceutical industry |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Japan to 2014Introduction / Pharmaceuticals Logistics Spending in Japan to 2014 assesses prospects for logistics in pharmaceutical industry. It |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Malaysia to 2014Introduction / Pharmaceuticals Logistics Spending in Malaysia to 2014 assesses prospects for logistics in pharmaceutical industry. |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Mexico to 2014Introduction / Pharmaceuticals Logistics Spending in Mexico to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Poland to 2014Introduction / Pharmaceuticals Logistics Spending in Poland to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Portugal to 2014Introduction / Pharmaceuticals Logistics Spending in Portugal to 2014 assesses the prospects for logistics in pharmaceutical indus |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Russia to 2014Introduction / Pharmaceuticals Logistics Spending in Russia to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Singapore to 2014Introduction / Pharmaceuticals Logistics Spending in Singapore to 2014 assesses prospects for logistics in pharmaceutical industry |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Spain to 2014Introduction / Pharmaceuticals Logistics Spending in Spain to 2014 assesses the prospects for logistics in pharmaceutical industry |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in Switzerland to 2014Introduction / Pharmaceuticals Logistics Spending in Switzerland to 2014 assesses the prospects for logistics in pharmaceutical in |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in the Netherlands to 2014Introduction / Pharmaceuticals Logistics Spending in the Netherlands to 2014 assesses the prospects for logistics pharmaceutical i |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in the UK to 2014Introduction / Pharmaceuticals Logistics Spending in the UK to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in the United Arab Emirates to 2014Introduction / Pharmaceuticals Logistics Spending in United Arab Emirates to 2014. It provides information on total logistics (by |
2011 | 695,00$ |
Pharmaceuticals Logistics Spending in the US to 2014Introduction / Pharmaceuticals Logistics Spending in the US to 2014 assesses the prospects for logistics in pharmaceutical industr |
2011 | 695,00$ |
Medicated Skin Products Market in Japan to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segm |
2011 | 350,00$ |
Medicated Skin Products Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and s |
2011 | 350,00$ |
Medicated Skin Products Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Medicated Skin Products Market in Sweden to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Medicated Skin Products Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market an |
2011 | 350,00$ |
Medicated Skin Products Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Medicated Skin Products Market in Thailand to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and s |
2011 | 350,00$ |
Medicated Skin Products Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for marke |
2011 | 350,00$ |
Medicated Skin Products Market in the UK to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Medicated Skin Products Market in the US to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Medicated Skin Products Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for |
2011 | 350,00$ |
Medicated Skin Products Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Medicated Skin Products Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Cough and Cold Preparations Market in Japan to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Cough and Cold Preparations Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Cough and Cold Preparations Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for mark |
2011 | 350,00$ |
Cough and Cold Preparations Market in Sweden to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Cough and Cold Preparations Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for marke |
2011 | 350,00$ |
Cough and Cold Preparations Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Cough and Cold Preparations Market in Thailand to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Cough and Cold Preparations Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for m |
2011 | 350,00$ |
Cough and Cold Preparations Market in the UK to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Cough and Cold Preparations Market in the US to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Cough and Cold Preparations Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource |
2011 | 350,00$ |
Cough and Cold Preparations Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Cough and Cold Preparations Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market an |
2011 | 350,00$ |
First Aid Kits Market in Japan to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level |
2011 | 350,00$ |
First Aid Kits Market in Malaysia to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le |
2011 | 350,00$ |
First Aid Kits Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen |
2011 | 350,00$ |
First Aid Kits Market in Sweden to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve |
2011 | 350,00$ |
First Aid Kits Market in Switzerland to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and segment |
2011 | 350,00$ |
First Aid Kits Market in Taiwan to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve |
2011 | 350,00$ |
First Aid Kits Market in Thailand to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le |
2011 | 350,00$ |
First Aid Kits Market in the Philippines to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
First Aid Kits Market in the UK to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve |
2011 | 350,00$ |
First Aid Kits Market in the US to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve |
2011 | 350,00$ |
First Aid Kits Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for market an |
2011 | 350,00$ |
First Aid Kits Market in Uruguay to 2014 (OTC Healthcare)Introduction / / First Aid Kits Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segment lev |
2011 | 350,00$ |
Plasters and Bandages Market in Japan to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen |
2011 | 350,00$ |
Plasters and Bandages Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Plasters and Bandages Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Plasters and Bandages Market in Sweden to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Plasters and Bandages Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Plasters and Bandages Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Plasters and Bandages Market in Thailand to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Plasters and Bandages Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Plasters and Bandages Market in the UK to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Plasters and Bandages Market in the US to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme |
2011 | 350,00$ |
Plasters and Bandages Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma |
2011 | 350,00$ |
Plasters and Bandages Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Plasters and Bandages Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm |
2011 | 350,00$ |
Indigestion Preparations Market in Japan to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and seg |
2011 | 350,00$ |
Indigestion Preparations Market in Malaysia to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Indigestion Preparations Market in Saudi Arabia to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market |
2011 | 350,00$ |
Indigestion Preparations Market in Sweden to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Indigestion Preparations Market in Switzerland to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market a |
2011 | 350,00$ |
Indigestion Preparations Market in Taiwan to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Indigestion Preparations Market in Thailand to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and |
2011 | 350,00$ |
Indigestion Preparations Market in the Philippines to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for mark |
2011 | 350,00$ |
Indigestion Preparations Market in the UK to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Indigestion Preparations Market in the US to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and se |
2011 | 350,00$ |
Indigestion Preparations Market in United Arab Emirates to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for |
2011 | 350,00$ |
Indigestion Preparations Market in Uruguay to 2014 (OTC Healthcare)Introduction / / Indigestion Preparations Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and s |
2011 | 350,00$ |
Healthcare Equipment and Disposables Logistics Spending in Australia to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Australia to 2014 assesses the prospects for logistics. |
2011 | 695,00$ |
Healthcare Logistics Spending in Australia to 2014Introduction / Healthcare Logistics Spending in Australia to 2014 assesses the prospects for logistics in healthcare industry. It |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Austria to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Austria to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Austria to 2014Introduction / Healthcare Logistics Spending in Austria to 2014 assesses the prospects for logistics in healthcare industry. It pr |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Belgium to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Belgium to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Belgium to 2014Introduction / Healthcare Logistics Spending in Belgium to 2014 assesses the prospects for logistics in healthcare industry. It pr |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Brazil to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Brazil to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Brazil to 2014Introduction / Healthcare Logistics Spending in Brazil to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Canada to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Canada to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Canada to 2014Introduction / Healthcare Logistics Spending in Canada to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in China to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in China to 2014 assesses the prospects for logistics. It p |
2011 | 695,00$ |
Healthcare Logistics Spending in China to 2014Introduction / Healthcare Logistics Spending in China to 2014 assesses the prospects for logistics in healthcare industry. It prov |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in France to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in France to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in France to 2014Introduction / Healthcare Logistics Spending in France to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Germany to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Germany to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Germany to 2014Introduction / Healthcare Logistics Spending in Germany to 2014 assesses the prospects for logistics in healthcare industry. It pr |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Hungary to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Hungary to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Hungary to 2014Introduction / Healthcare Logistics Spending in Hungary to 2014 assesses the prospects for logistics in healthcare industry. It pr |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in India to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in India to 2014 assesses the prospects for logistics. It p |
2011 | 695,00$ |
Healthcare Logistics Spending in India to 2014Introduction / Healthcare Logistics Spending in India to 2014 assesses the prospects for logistics in healthcare industry. It prov |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Italy to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Italy to 2014 assesses the prospects for logistics. It p |
2011 | 695,00$ |
Healthcare Logistics Spending in Italy to 2014Introduction / Healthcare Logistics Spending in Italy to 2014 assesses the prospects for logistics in healthcare industry. It prov |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Japan to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Japan to 2014 assesses the prospects for logistics. It p |
2011 | 695,00$ |
Healthcare Logistics Spending in Japan to 2014Introduction / Healthcare Logistics Spending in Japan to 2014 assesses the prospects for logistics in healthcare industry. It prov |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Malaysia to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Malaysia to 2014 assesses the prospects for logistics. I |
2011 | 695,00$ |
Healthcare Logistics Spending in Malaysia to 2014Introduction / Healthcare Logistics Spending in Malaysia to 2014 assesses the prospects for logistics in healthcare industry. It p |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Mexico to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Mexico to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Mexico to 2014Introduction / Healthcare Logistics Spending in Mexico to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Poland to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Poland to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Poland to 2014Introduction / Healthcare Logistics Spending in Poland to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Portugal to 2014Introduction
/ Healthcare Equipment and Disposables Logistics Spending in Portugal to 2014 assesses the prospects for logistics. |
2011 | 695,00$ |
Healthcare Logistics Spending in Portugal to 2014Introduction
/ Healthcare Logistics Spending in Portugal to 2014 assesses the prospects for logistics in healthcare industry. It |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Russia to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Russia to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in Russia to 2014Introduction / Healthcare Logistics Spending in Russia to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Singapore to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Singapore to 2014 assesses the prospects for logistics.I |
2011 | 695,00$ |
Healthcare Logistics Spending in Singapore to 2014Introduction / Healthcare Logistics Spending in Singapore to 2014 assesses the prospects for logistics in healthcare industry. It |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Spain to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Spain to 2014 assesses the prospects for logistics. It p |
2011 | 695,00$ |
Healthcare Logistics Spending in Spain to 2014Introduction / Healthcare Logistics Spending in Spain to 2014 assesses the prospects for logistics in healthcare industry. It prov |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in Switzerland to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in Switzerland to 2014 assesses the prospects for logistics |
2011 | 695,00$ |
Healthcare Logistics Spending in Switzerland to 2014Introduction / Healthcare Logistics Spending in Switzerland to 2014 assesses the prospects for logistics in healthcare industry. I |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in the Netherlands to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in the Netherlands to 2014 assesses the prospects for logi |
2011 | 695,00$ |
Healthcare Logistics Spending in the Netherlands to 2014Introduction / Healthcare Logistics Spending in the Netherlands to 2014 assesses the prospects for logistics in healthcare industr |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in the UK to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in the UK to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in the UK to 2014Introduction / Healthcare Logistics Spending in UK to 2014 assesses the prospects for logistics in healthcare industry. It provide |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in the US to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in the US to 2014 assesses the prospects for logistics. It |
2011 | 695,00$ |
Healthcare Logistics Spending in the US to 2014Introduction / Healthcare Logistics Spending in the US to 2014 assesses the prospects for logistics in healthcare industry. It pro |
2011 | 695,00$ |
Healthcare Equipment and Disposables Logistics Spending in United Arab Emirates to 2014Introduction / Healthcare Equipment and Disposables Logistics Spending in United Arab Emirates to 2014 .It provides information on |
2011 | 695,00$ |
Healthcare Logistics Spending in UAE to 2014Introduction / Healthcare Logistics Spending in UAE to 2014 assesses the prospects for logistics in healthcare industry. It provid |
2011 | 695,00$ |
R&D Trends: Insulin Antidiabetics - The future is analogsIntroduction / / The insulin antidiabetic pipeline can be split between small manufacturers, often targeting reformulations of ex |
2011 | 3.800,00$ |
Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditionsIntroduction / / The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets ( |
2011 | 3.800,00$ |
Pharmaceutical Key Trends 2011 – Socio-Demographic and Economic Overview : Rising healthcare costs coupled with the economic downturn continue to shape the healthcare landscapeIntroduction / / Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding |
2011 | 1.900,00$ |
R&D Trends: Depression - Pipeline characterized by its depth and diversityIntroduction / / Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafa |
2011 | 3.800,00$ |
R&D Trends: Autism Spectrum Disorders - Unknown etiology and low industry interest hinders pipeline progressionIntroduction / / Since 2006, two drugs have gained FDA approval for the symptomatic treatment of irritability in autism spectrum |
2011 | 3.800,00$ |
R&D Trends: Sepsis - Improvements in clinical trial design and advances in biomarker research hold the key to a tailored approach to sepsis therapyIntroduction / / Despite Eli Lilly’s Xigris being the only licensed therapeutic, the sepsis market remains commercially attractiv |
2011 | 3.800,00$ |
Health Concerns & Alcoholic Beverage Preferences: Implications for NPDIntroduction / / As health has become a more important issue for consumers generally, the influence it has had on alcoholic bever |
2011 | 3.450,00$ |
Epidemiology: Major Orthopedic Surgery – On the rise as the global elderly population continues to growIntroduction / / In 2010, Datamonitor estimates that there were 5.3 million orthopedic surgeries in the seven major markets. Due |
2011 | 5.700,00$ |
R&D Trends: Obesity - 2006–2011: obesity’s lean yearsIntroduction / / Modest efficacy results and lingering safety concerns have meant that developers of obesity drugs have failed to |
2011 | 3.800,00$ |
AstraZeneca: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutica |
2011 | 5.700,00$ |
GlaxoSmithKline plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceu |
2011 | 5.700,00$ |
Genzyme CorporationIntroduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se |
2011 | 5.700,00$ |
Abbott Laboratories: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sec |
2011 | 5.700,00$ |
Mitsubishi Tanabe Pharma Corp.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmac |
2011 | 5.700,00$ |
R&D Trends: Multiple Sclerosis - Progressive subtypes remain underserved in expansive pipelineIntroduction / / In recent years, there has been a paradigm shift in the pipeline for new MS therapies, with a growing number of |
2011 | 3.800,00$ |
UK Healthcare Cash Plans 2011Introduction / / This brief provides a detailed study of the UK healthcare cash plan market, with information on market size and |
2011 | 2.795,00$ |
Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growthIntroduction / / To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Joh |
2011 | 1.900,00$ |
Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemicIntroduction / / The World Health Organization (WHO) estimates that worldwide, there are currently 220 million people living with |
2010 | 7.600,00$ |
Shionogi & Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Shionogi in the prescription pharmaceutical s |
2011 | 5.700,00$ |
Epidemiology: InsomniaIntroduction / / In this analysis, Datamonitor estimates that there were a total of 53 million cases of insomnia in 2010 in the s |
2011 | 5.700,00$ |
Bristol-Myers Squibb Co.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription phar |
2011 | 5.700,00$ |
Epidemiology: Allergic Rhinitis - Allergic rhinitis is highly prevalent yet significantly under-diagnosedIntroduction / / By 2020, approximately 157 million adults and 31 million children will be living with allergic rhinitis across t |
2011 | 3.800,00$ |
Commercial Insight: Osteoporosis – Market players maximize revenue growth before the next challenging phaseAnalysis of global osteoporosis prescriptions from 2005–09, split by geographical region (including emerging markets), drug class, |
2010 | 15.200,00$ |
Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipelinePatient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China).Review of the key cl |
2010 | 11.400,00$ |
Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?Analysis of global osteoporosis prescriptions from 2005–09, split by geographical region (including emerging markets), drug class, |
2010 | 3.800,00$ |
Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and TurkeyCurrent epidemiology of HBV and HCV, including prevalence, diagnosis and treatment rates as well as patient split by line and choi |
2010 | 15.200,00$ |
Pipeline and Commercial Insight: Testosterone Replacement Therapy - Topical formulations drive market growthPatient potential analysis across the seven major marketsReview of the key needs supported by key opinion leadersCurrent and futur |
2010 | 15.200,00$ |
Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the marketPatient potential analysis across the seven major marketsReview of the key needs supported by key opinion leaders from the US and |
2010 | 15.200,00$ |
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severitySnapshot of the current rheumatoid arthritis market based on a survey of 183 rheumatologists, supported with views from key opinio |
2010 | 15.200,00$ |
Pipeline and Commercial Insight: Pneumococcal and Meningococcal VaccinesIntroduction / / Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that cou |
2010 | 15.200,00$ |
Les Laboratoires Servier: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical se |
2010 | 5.700,00$ |
King Pharmaceuticals Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for King in the prescription pharmaceutical secto |
2010 | 5.700,00$ |
Merck & Co., Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutica |
2010 | 5.700,00$ |
Sanofi-Aventis: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceut |
2010 | 5.700,00$ |
Novartis AG: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical s |
2010 | 5.700,00$ |
GlaxoSmithKline plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceu |
2010 | 5.700,00$ |
Pfizer Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscapeIntroduction / / The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers inclu |
2010 | 7.600,00$ |
Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic salesIntroduction / / Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster produ |
2010 | 15.200,00$ |
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presentsIntroduction / / The Russian pharmaceutical market generated $10.1 billion in sales in 2009, growing by 14.5% between 2008 and 20 |
2010 | 7.600,00$ |
China Pharmaceutical Market OverviewIntroduction / The Chinese hospital prescription pharma market generated sales of $22.9 billion in 2009, with an annual growth rat |
2010 | 7.600,00$ |
Allergan Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Allergan in the prescription pharmaceutical s |
2010 | 5.700,00$ |
Chugai Pharmaceutical Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Novo Nordisk A/S: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Novo Nordisk in the prescription pharmaceutic |
2010 | 5.700,00$ |
Teva Pharma. Industries Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical secto |
2010 | 5.700,00$ |
CSL Limited: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for CSL in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Shire plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Mylan Inc.: PharmaVitae ProfileIntroduction / / The analysis examines the historical and forecast performance for Mylan in the generic prescription pharmaceutic |
2010 | 5.700,00$ |
Boehringer Ingelheim GmbH: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the prescription phar |
2010 | 5.700,00$ |
UCB S.A.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Forest Laboratories Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Apotex Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Apotex in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
AstraZeneca plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutica |
2010 | 5.700,00$ |
Celgene Corporation: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical se |
2010 | 5.700,00$ |
Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progressIntroduction / / There are currently 100 drugs in the pipeline for melanoma, thyroid cancer and neuroendocrine tumors with 16 in |
2010 | 11.400,00$ |
Johnson & Johnson: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Johnson & Johnson in the prescription pharmac |
2010 | 5.700,00$ |
H. Lundbeck A/S: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Lundbeck in the prescription pharmaceutical s |
2010 | 5.700,00$ |
Cephalon Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Cephalon in the prescription pharmaceutical s |
2010 | 11.400,00$ |
Warner-Chilcott Plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Warner Chilcott in the prescription pharmaceu |
2010 | 5.700,00$ |
Watson Pharmaceuticals Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Daiichi Sankyo Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Daiichi Sankyo in the prescription pharmaceut |
2010 | 5.700,00$ |
Baxter International Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Otsuka Pharmaceutical Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Alcon Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growthIntroduction / / The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005–09 |
2010 | 11.400,00$ |
India Pharmaceutical Market Overview Growing economic wealth fuels pharma market growth, but generics dominateThe prescription pharmaceutical market in India generated $7.1 billion in sales in 2009, with an annual growth rate of 18.1% betwe |
2010 | 7.600,00$ |
Healthcare Regulatory Update: The United Arab EmiratesIntroduction / / The fragmented nature of the healthcare systems in the United Arab Emirates remains despite the implementation o |
2010 | 3.800,00$ |
Pharmaceutical Key Trends 2010Introduction / / Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode |
2010 | 11.400,00$ |
Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continuesOverview of erectile dysfunction, premature ejaculation and female sexual dysfunction disorders including epidemiology and key unm |
2010 | 7.600,00$ |
Pharmaceutical Licensing OverviewOverview of Big Pharma's current and anticipated future reliance on externally sourced productsOverview of drivers and resistors o |
2010 | 15.200,00$ |
Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targetsAnalysis of the market for respiratory viral infections across the US, Japan, France, Italy, Germany, Spain and the UKStrategic an |
2010 | 3.800,00$ |
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy optionsSegmentation and analysis of products across all stages of the IBD pipeline with in-depth discussion of key Phase II and III pipel |
2010 | 11.400,00$ |
Pharmaceutical M&A in the Asia-Pacific Region – India and China drive regional activity but Japan still dominates high value transactionsIntroduction / / Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle clas |
2010 | 7.600,00$ |
Infectious Diseases Vaccine Market OverviewIntroduction / / Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Phar |
2010 | 15.200,00$ |
Pharmaceutical Company Outlook to 2015Introduction / / Historical and forecast analysis of the PharmaVitae Universe from 2003 through to 2015. Strategic dynamics wit |
2010 | 7.600,00$ |
Pharmaceutical Licensing and Alliances in the Asia-Pacific Region – Pharma enhances its focus on APAC marketsIntroduction / / While the Japanese market with its increasingly globally-minded pharma companies still dominates deal activities |
2010 | 7.600,00$ |
Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelinesIntroduction / / While general COPD treatment patterns are consistent across the emerging markets compared to the US, some key di |
2010 | 15.200,00$ |
Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized marketIntroduction / / The epilepsy market has become increasingly competitive following the launch of Vimpat (lacosamide; UCB) in the |
2010 | 15.200,00$ |
Stakeholder Opinions: Hepatocellular cancerIntroduction / Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large pa |
2010 | 3.800,00$ |
Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseasesIntroduction / Dengue, Japanese encephalitis and West Nile virus are major causes of disease worldwide. Dual market pricing strate |
2010 | 3.800,00$ |
Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-developmentIntroduction / The treatment of cancer has seen a dramatic shift with the addition of molecular targeted therapies. The mixed and |
2011 | 1.900,00$ |
Eisai Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sect |
2011 | 5.700,00$ |
Pharmaceutical Key Trends 2011 – Biosimilar Market OverviewIntroduction / / In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more th |
2011 | 3.800,00$ |
Pipeline Insight: AntibacterialsIntroduction / / The antibacterial pipeline is robust with regards to new drugs for the treatment of Gram-positive pathogens, par |
2011 | 11.400,00$ |
Reforms to the Pharmaceutical Benefits Scheme in AustraliaIntroduction / / As further statutory price cuts and “expanded and accelerated” price disclosure is applied to substitutable medi |
2011 | 500,00$ |
Italy Pharmaceutical Market Overview Generic penetration set to riseIntroduction / / The prescription pharmaceutical market in Italy was valued at $24.9 billion in 2009. Key growth drivers for bran |
2010 | 11.400,00$ |
Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developmentsIntroduction / / After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in |
2010 | 15.200,00$ |
Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesicsIntroduction / / The treatment of moderate to severe acute pain is dominated by opioids. While they offer excellent pain relief, |
2010 | 15.200,00$ |
Stakeholder Insight: Gastric CancerIntroduction / / Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric canc |
2010 | 15.200,00$ |
Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptakeIntroduction / / The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma in |
2010 | 11.400,00$ |
Pipeline and Commercial Insight: Alzheimer's Disease - Market cautiously awaits the first generation of disease-modifying therapiesIntroduction / / Current management of Alzheimer’s disease is wholly inadequate, providing only symptomatic benefit to patients i |
2010 | 15.200,00$ |
US Pharmaceutical Market Overview – Healthcare reform, economic pressures and the patent cliff set to impact PharmaIntroduction / / The US prescription pharmaceutical market was valued at $279 billion in 2009, with an annual growth rate of 5.5% |
2010 | 11.400,00$ |
Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmissionIntroduction / / Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious compl |
2010 | 3.800,00$ |
Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019Introduction / / The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal thera |
2010 | 15.200,00$ |
Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growthIntroduction / / Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 an |
2010 | 7.600,00$ |
Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosperIntroduction / / The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic exte |
2010 | 15.200,00$ |
Commercial Insight: Top 20 Cancer Therapy BrandsIntroduction / / The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy |
2010 | 15.200,00$ |
Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosionIntroduction / / Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and pros |
2010 | 15.200,00$ |
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapyIntroduction / / Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ov |
2010 | 3.800,00$ |
Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competitionIntroduction / / In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between |
2010 | 15.200,00$ |
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive.Introduction / / Datamonitor forecasts that the insulin antidiabetics market will grow from 10.6 billion in 2009 to $16.4 billion |
2010 | 11.400,00$ |
Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomesIntroduction / / Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) |
2010 | 11.400,00$ |
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.Introduction / / Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major |
2010 | 11.400,00$ |
Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for successIntroduction / / The urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new p |
2010 | 15.200,00$ |
Abbott Laboratories: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Prescription Pharmaceutical Market Sales Overview – Analysis of prescription pharmaceutical sales across 12 major marketsIntroduction / / Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan |
2010 | 15.200,00$ |
Bristol-Myers Squibb Co.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription phar |
2010 | 5.700,00$ |
Brand Erosion Post-Patent Expiry – An analysis of small molecule brand erosion post-patent expiryIntroduction
/
/ Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic co |
2010 | 15.200,00$ |
Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacyIntroduction
/
/ At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant event |
2011 | 15.200,00$ |
Forecast Insight: AntibacterialsIntroduction / / Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as |
2011 | 15.200,00$ |
Commercial Insight: Hepatitis B in ChinaIntroduction / / Fuelled by the increasing use of new, expensive drugs, and the anticipated launch of new therapies, the Chinese |
2011 | 5.700,00$ |
Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent ExpiryIntroduction / / Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic comp |
2011 | 3.800,00$ |
Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales OverviewIntroduction / / Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan |
2011 | 3.800,00$ |
R&D Trends: Hepatitis CIntroduction / / Pegylated interferon in combination with ribavirin is the current standard of care for hepatitis C. While effect |
2011 | 3.800,00$ |
R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipelineIntroduction / / The 2011 pipeline shows strong interest in immunotherapy, which makes up 42% of products in development. Advance |
2011 | 3.800,00$ |
R&D Trends: Psoriasis - Pipeline outlook following withdrawal of key regulatory filingIntroduction / / Datamonitor identified 128 products in development, with a notable focus on interleukin (IL) targets. 2009 marke |
2011 | 3.800,00$ |
Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensifyIntroduction / / Healthcare expenditure is growing fast in all markets, driven by aging populations, a growing prevalence of chro |
2011 | 3.800,00$ |
R&D Trends: HIV - An active pipeline faces fierce competition in the HIV marketIntroduction / / Although there are a number of novel approaches in early-stage development for HIV, fierce competition is thinni |
2011 | 3.800,00$ |
R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatmentIntroduction / / Over the last 12 months, there have been encouraging developments in the osteoporosis pipeline, with new therapi |
2011 | 3.800,00$ |
Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patientsIntroduction / The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with |
2011 | 11.400,00$ |
Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and ArgentinaIntroduction / / Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed |
2010 | 3.800,00$ |
Stakeholder Opinions: Cervical and Endometrial Cancer - Opportunities remain outside the big gynecologic malignanciesIntroduction / / In cervical cancer, screening and human papillomavirus (HPV) vaccination have gradually shifted the focus toward |
2010 | 3.800,00$ |
Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated marketIntroduction / / Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drug |
2010 | 3.800,00$ |
Commercial Insight: Top 20 Oncology Therapy Brands in Australia Revenues of targeted therapies soar while sales of cytotoxics and antihormonals declineIntroduction / / The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% sin |
2010 | 5.700,00$ |
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugsIntroduction / / The five tumor types covered in this report are set to account for nearly 898,000 new patients in 2010. Collecti |
2010 | 11.400,00$ |
Pipeline Insight: Leukemias Underserved patient populations offer potential for market growthIntroduction / / Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population sti |
2010 | 11.400,00$ |
Stakeholder Opinions: Traumatic Brain Injury Hormonal therapy generates optimismIntroduction / / There remains no approved pharmacological or cellular treatment to improve the outcome of survivors of traumatic |
2010 | 3.800,00$ |
Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities for emerging therapiesIntroduction / / The commercial success of Rituxan in the treatment of NHL and Velcade and Revlimid in the treatment of MM has at |
2010 | 11.400,00$ |
Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growthIntroduction / / Small molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs curre |
2010 | 11.400,00$ |
Commercial Insight: Opioids in AustraliaIntroduction / / The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the |
2010 | 5.700,00$ |
Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunityIntroduction / / Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerg |
2010 | 3.800,00$ |
Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signaturesIntroduction / / The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metast |
2010 | 3.800,00$ |
UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growthIntroduction / / The UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growin |
2010 | 11.400,00$ |
Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agentsIntroduction / / In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10 |
2010 | 15.200,00$ |
Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potentialAnalysis of the patient potential of spinal cord injury across the seven major markets and rest of world.Review of key unmet clini |
2010 | 3.800,00$ |
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized marketAnalysis of current epilepsy treatments, unmet market needs and the impact of generics.Review of the late-stage epilepsy pipeline, |
2010 | 11.400,00$ |
Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depressionIntroduction / / Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in |
2010 | 15.200,00$ |
Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated marketIntroduction
/
/ Prescribing trends reveal that the MDD market is receptive to alternative modes of actions at later lines of t |
2010 | 15.200,00$ |
Asia-Pacific Healthcare Vertical Market Map 2010Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust |
2011 | 10.000,00$ |
Global Top 10 Pharmaceutical Companies- Industry, Financial and SWOT AnalysisDatamonitor's Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. T |
2011 | 1.895,00$ |
Americas Healthcare Vertical Market Map 2010Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust |
2011 | 10.000,00$ |
Antibacterials: Market ForecastIntroduction / / Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as |
2011 | 15.200,00$ |
Australia Regional Wealth Markets Database 2010Introduction / / While Australia was spared a recession, its wealthy suffered due to the global financial crisis. The first of it |
2011 | 5.000,00$ |
BRIC Healthcare Vertical Market Map 2010Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust |
2011 | 10.000,00$ |
Commercial Insight: Cardiovascular and Metabolic Market ForecastIntroduction / / Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and met |
2011 | 15.200,00$ |
Epidemiology: Cervical CancerIntroduction / / Historical, and consequently future, incidence trends of cervical cancer are primarily related to access to and |
2011 | 5.700,00$ |
Epidemiology: Hepatitis CIntroduction / / In 2010, Datamonitor estimates that there were about 6.9 million cases of hepatitis C virus in adults aged over |
2011 | 5.700,00$ |
Epidemiology: Parkinson's DiseaseIntroduction
/
/ In this report, Datamonitor has estimated that there were a total of 1.5 million cases of Parkinson’s disease |
2011 | 5.700,00$ |
Epidemiology: Urinary IncontinenceIntroduction / / In 2010, Datamonitor estimates that there will be about 83.4 million prevalent cases of urinary incontinence (UI |
2011 | 5.700,00$ |
Neuropathic Pain Market ForecastIntroduction / / At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events |
2011 | 15.200,00$ |
UAE Healthcare Vertical Market Map 2010Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust |
2011 | 10.000,00$ |
OTC Healthcare in the Czech Republic to 2014IntroductionThis databook provides key data and information on the OTC healthcare market in the Czech Republic. This report is a c |
2011 | 495,00$ |
OTC Healthcare in Turkey to 2014IntroductionThis databook provides key data and information on the OTC healthcare market in Turkey. This report is a comprehensive |
2011 | 495,00$ |
Indigestion Preparations Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Argentina (OTC Healthc |
2011 | 350,00$ |
Indigestion Preparations Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Asia-Pacific (OTC Heal |
2011 | 350,00$ |
Indigestion Preparations Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Austria (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Belgium (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Brazil (OTC Healthcare |
2011 | 350,00$ |
Indigestion Preparations Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Bulgaria (OTC Healthca |
2011 | 350,00$ |
Indigestion Preparations Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in China (OTC Healthcare) |
2011 | 350,00$ |
Indigestion Preparations Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Croatia (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Eastern Europe (OTC He |
2011 | 350,00$ |
Indigestion Preparations Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Latin America (OTC Hea |
2011 | 350,00$ |
Indigestion Preparations Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Middle East and Africa |
2011 | 350,00$ |
Indigestion Preparations Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in North America (OTC Hea |
2011 | 350,00$ |
Indigestion Preparations Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Western Europe (OTC He |
2011 | 350,00$ |
Topical OTC Medicines Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Israel (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Mexico (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Nigeria (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Pakistan (OTC Healthcare) |
2011 | 350,00$ |
Topical OTC Medicines Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Romania (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Singapore (OTC Healthcare |
2011 | 350,00$ |
Topical OTC Medicines Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Slovenia (OTC Healthcare) |
2011 | 350,00$ |
Indigestion Preparations Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Denmark (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Egypt (OTC Healthcare) |
2011 | 350,00$ |
Indigestion Preparations Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Finland (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in France (OTC Healthcare |
2011 | 350,00$ |
Indigestion Preparations Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Germany (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Greece (OTC Healthcare |
2011 | 350,00$ |
Indigestion Preparations Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Hong Kong (OTC Healthc |
2011 | 350,00$ |
Indigestion Preparations Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Hungary (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in India (OTC Healthcare) |
2011 | 350,00$ |
Indigestion Preparations Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Indonesia (OTC Healthc |
2011 | 350,00$ |
Indigestion Preparations Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Ireland (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Israel (OTC Healthcare |
2011 | 350,00$ |
Indigestion Preparations Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Mexico (OTC Healthcare |
2011 | 350,00$ |
Indigestion Preparations Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in the Netherlands (OTC H |
2011 | 350,00$ |
Indigestion Preparations Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Nigeria (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Pakistan (OTC Healthca |
2011 | 350,00$ |
Indigestion Preparations Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Romania (OTC Healthcar |
2011 | 350,00$ |
Indigestion Preparations Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Singapore (OTC Healthc |
2011 | 350,00$ |
Indigestion Preparations Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Slovenia (OTC Healthca |
2011 | 350,00$ |
Indigestion Preparations Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in South Africa (OTC Heal |
2011 | 350,00$ |
Indigestion Preparations Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in South Korea (OTC Healt |
2011 | 350,00$ |
Indigestion Preparations Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Spain (OTC Healthcare) |
2011 | 350,00$ |
Indigestion Preparations Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Venezuela (OTC Healthc |
2011 | 350,00$ |
Indigestion Preparations Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Vietnam (OTC Healthcar |
2011 | 350,00$ |
Medicated Skin Products Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Asia-Pacific (OTC Healt |
2011 | 350,00$ |
Medicated Skin Products Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Eastern Europe (OTC Hea |
2011 | 350,00$ |
Medicated Skin Products Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Latin America (OTC Heal |
2011 | 350,00$ |
Medicated Skin Products Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Middle East and Africa |
2011 | 350,00$ |
Medicated Skin Products Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in North America (OTC Heal |
2011 | 350,00$ |
Medicated Skin Products Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Western Europe (OTC Hea |
2011 | 350,00$ |
Medicated Skin Products Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Argentina (OTC Healthca |
2011 | 350,00$ |
Medicated Skin Products Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Austria (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Belgium (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Brazil (OTC Healthcare) |
2011 | 350,00$ |
Medicated Skin Products Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Bulgaria (OTC Healthcar |
2011 | 350,00$ |
Medicated Skin Products Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in China (OTC Healthcare). |
2011 | 350,00$ |
Medicated Skin Products Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Croatia (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Denmark (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Egypt (OTC Healthcare). |
2011 | 350,00$ |
Medicated Skin Products Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Finland (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in France (OTC Healthcare) |
2011 | 350,00$ |
Medicated Skin Products Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Germany (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Greece (OTC Healthcare) |
2011 | 350,00$ |
Medicated Skin Products Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Hong Kong (OTC Healthca |
2011 | 350,00$ |
Medicated Skin Products Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Hungary (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in India (OTC Healthcare). |
2011 | 350,00$ |
Medicated Skin Products Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Indonesia (OTC Healthca |
2011 | 350,00$ |
Medicated Skin Products Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Ireland (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Israel (OTC Healthcare) |
2011 | 350,00$ |
Medicated Skin Products Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Mexico (OTC Healthcare) |
2011 | 350,00$ |
Medicated Skin Products Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in the Netherlands (OTC He |
2011 | 350,00$ |
Medicated Skin Products Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Nigeria (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Pakistan (OTC Healthcar |
2011 | 350,00$ |
Medicated Skin Products Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Romania (OTC Healthcare |
2011 | 350,00$ |
Medicated Skin Products Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Singapore (OTC Healthca |
2011 | 350,00$ |
Medicated Skin Products Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Slovenia (OTC Healthcar |
2011 | 350,00$ |
Medicated Skin Products Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in South Africa (OTC Healt |
2011 | 350,00$ |
Medicated Skin Products Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in South Korea (OTC Health |
2011 | 350,00$ |
Medicated Skin Products Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Spain (OTC Healthcare). |
2011 | 350,00$ |
Medicated Skin Products Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Venezuela (OTC Healthca |
2011 | 350,00$ |
Medicated Skin Products Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Vietnam (OTC Healthcare |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Asia-Pacific (OTC |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Eastern Europe (O |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Latin America (OT |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Middle East and A |
2011 | 350,00$ |
Other OTC Healthcare Products Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in North America (OT |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Western Europe (O |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Argentina (OTC He |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Austria (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Belgium (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Brazil (OTC Healt |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Bulgaria (OTC Hea |
2011 | 350,00$ |
Other OTC Healthcare Products Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in China (OTC Health |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Croatia (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Denmark (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Egypt (OTC Health |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Finland (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in France (OTC Healt |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Germany (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Greece (OTC Healt |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Hong Kong (OTC He |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Hungary (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in India (OTC Health |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Indonesia (OTC He |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Ireland (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Israel (OTC Healt |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Mexico (OTC Healt |
2011 | 350,00$ |
Other OTC Healthcare Products Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in the Netherlands ( |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Nigeria (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Pakistan (OTC Hea |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Romania (OTC Heal |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Singapore (OTC He |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Slovenia (OTC Hea |
2011 | 350,00$ |
Other OTC Healthcare Products Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in South Africa (OTC |
2011 | 350,00$ |
Other OTC Healthcare Products Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in South Korea (OTC |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Spain (OTC Health |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Venezuela (OTC He |
2011 | 350,00$ |
Other OTC Healthcare Products Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Vietnam (OTC Heal |
2011 | 350,00$ |
Plasters and Bandages Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Asia-Pacific (OTC Healthc |
2011 | 350,00$ |
Plasters and Bandages Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Eastern Europe (OTC Healt |
2011 | 350,00$ |
Plasters and Bandages Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Latin America (OTC Health |
2011 | 350,00$ |
Plasters and Bandages Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Middle East and Africa (O |
2011 | 350,00$ |
Plasters and Bandages Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in North America (OTC Health |
2011 | 350,00$ |
Plasters and Bandages Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Western Europe (OTC Healt |
2011 | 350,00$ |
Plasters and Bandages Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Argentina (OTC Healthcare |
2011 | 350,00$ |
Plasters and Bandages Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Austria (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Belgium (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Brazil (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Bulgaria (OTC Healthcare) |
2011 | 350,00$ |
Plasters and Bandages Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in China (OTC Healthcare). T |
2011 | 350,00$ |
Plasters and Bandages Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Croatia (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Denmark (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Egypt (OTC Healthcare). T |
2011 | 350,00$ |
Plasters and Bandages Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Finland (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in France (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Germany (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Greece (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Hong Kong (OTC Healthcare |
2011 | 350,00$ |
Plasters and Bandages Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Hungary (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in India (OTC Healthcare). T |
2011 | 350,00$ |
Plasters and Bandages Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Indonesia (OTC Healthcare |
2011 | 350,00$ |
Plasters and Bandages Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Ireland (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Israel (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Mexico (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in the Netherlands (OTC Heal |
2011 | 350,00$ |
Plasters and Bandages Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Nigeria (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Pakistan (OTC Healthcare) |
2011 | 350,00$ |
Plasters and Bandages Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Romania (OTC Healthcare). |
2011 | 350,00$ |
Plasters and Bandages Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Singapore (OTC Healthcare |
2011 | 350,00$ |
Plasters and Bandages Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Slovenia (OTC Healthcare) |
2011 | 350,00$ |
Plasters and Bandages Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in South Africa (OTC Healthc |
2011 | 350,00$ |
Plasters and Bandages Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in South Korea (OTC Healthca |
2011 | 350,00$ |
Plasters and Bandages Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Spain (OTC Healthcare). T |
2011 | 350,00$ |
Plasters and Bandages Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Venezuela (OTC Healthcare |
2011 | 350,00$ |
Plasters and Bandages Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Vietnam (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Asia-Pacific (OTC Healthc |
2011 | 350,00$ |
Topical OTC Medicines Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Eastern Europe (OTC Healt |
2011 | 350,00$ |
Topical OTC Medicines Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Latin America (OTC Health |
2011 | 350,00$ |
Topical OTC Medicines Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Middle East and Africa (O |
2011 | 350,00$ |
Topical OTC Medicines Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in North America (OTC Health |
2011 | 350,00$ |
Topical OTC Medicines Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Western Europe (OTC Healt |
2011 | 350,00$ |
Topical OTC Medicines Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Argentina (OTC Healthcare |
2011 | 350,00$ |
Topical OTC Medicines Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Austria (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Belgium (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Brazil (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Bulgaria (OTC Healthcare) |
2011 | 350,00$ |
Topical OTC Medicines Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in China (OTC Healthcare). T |
2011 | 350,00$ |
Topical OTC Medicines Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Croatia (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Denmark (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Egypt (OTC Healthcare). T |
2011 | 350,00$ |
Topical OTC Medicines Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Finland (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in France (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Germany (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Greece (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Hong Kong (OTC Healthcare |
2011 | 350,00$ |
Topical OTC Medicines Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Hungary (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in India (OTC Healthcare). T |
2011 | 350,00$ |
Topical OTC Medicines Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Indonesia (OTC Healthcare |
2011 | 350,00$ |
Topical OTC Medicines Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Ireland (OTC Healthcare). |
2011 | 350,00$ |
Topical OTC Medicines Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in the Netherlands (OTC Heal |
2011 | 350,00$ |
Topical OTC Medicines Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in South Africa (OTC Healthc |
2011 | 350,00$ |
Topical OTC Medicines Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in South Korea (OTC Healthca |
2011 | 350,00$ |
Topical OTC Medicines Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Spain (OTC Healthcare). T |
2011 | 350,00$ |
Topical OTC Medicines Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Venezuela (OTC Healthcare |
2011 | 350,00$ |
Topical OTC Medicines Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Vietnam (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Asia-Pacific (OTC Healthc |
2011 | 350,00$ |
Traditional Medicines Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Eastern Europe (OTC Healt |
2011 | 350,00$ |
Traditional Medicines Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Latin America (OTC Health |
2011 | 350,00$ |
Traditional Medicines Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Middle East and Africa (O |
2011 | 350,00$ |
Traditional Medicines Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in North America (OTC Health |
2011 | 350,00$ |
Traditional Medicines Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Western Europe (OTC Healt |
2011 | 350,00$ |
Traditional Medicines Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Argentina (OTC Healthcare |
2011 | 350,00$ |
Traditional Medicines Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Austria (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Belgium (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Brazil (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Bulgaria (OTC Healthcare) |
2011 | 350,00$ |
Traditional Medicines Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in China (OTC Healthcare). T |
2011 | 350,00$ |
Traditional Medicines Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Croatia (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Denmark (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Egypt (OTC Healthcare). T |
2011 | 350,00$ |
Traditional Medicines Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Finland (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in France (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Germany (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Greece (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Hong Kong (OTC Healthcare |
2011 | 350,00$ |
Traditional Medicines Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Hungary (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in India (OTC Healthcare). T |
2011 | 350,00$ |
Traditional Medicines Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Indonesia (OTC Healthcare |
2011 | 350,00$ |
Traditional Medicines Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Ireland (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Israel (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Mexico (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in the Netherlands (OTC Heal |
2011 | 350,00$ |
Traditional Medicines Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Nigeria (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Pakistan (OTC Healthcare) |
2011 | 350,00$ |
Traditional Medicines Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Romania (OTC Healthcare). |
2011 | 350,00$ |
Traditional Medicines Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Singapore (OTC Healthcare |
2011 | 350,00$ |
Traditional Medicines Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Slovenia (OTC Healthcare) |
2011 | 350,00$ |
Traditional Medicines Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in South Africa (OTC Healthc |
2011 | 350,00$ |
Traditional Medicines Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in South Korea (OTC Healthca |
2011 | 350,00$ |
Traditional Medicines Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Spain (OTC Healthcare). T |
2011 | 350,00$ |
Traditional Medicines Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Venezuela (OTC Healthcare |
2011 | 350,00$ |
Traditional Medicines Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Traditional Medicines Market in Vietnam (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Asia-Pacific (OTC Healthc |
2011 | 350,00$ |
Vitamins and Minerals Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Eastern Europe (OTC Healt |
2011 | 350,00$ |
Vitamins and Minerals Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Latin America (OTC Health |
2011 | 350,00$ |
Vitamins and Minerals Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Middle East and Africa (O |
2011 | 350,00$ |
Vitamins and Minerals Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in North America (OTC Health |
2011 | 350,00$ |
Vitamins and Minerals Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Western Europe (OTC Healt |
2011 | 350,00$ |
Vitamins and Minerals Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Argentina (OTC Healthcare |
2011 | 350,00$ |
Vitamins and Minerals Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Austria (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Belgium (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Brazil (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Bulgaria (OTC Healthcare) |
2011 | 350,00$ |
Vitamins and Minerals Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in China (OTC Healthcare). T |
2011 | 350,00$ |
Vitamins and Minerals Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Croatia (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Denmark (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Egypt (OTC Healthcare). T |
2011 | 350,00$ |
Vitamins and Minerals Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Finland (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in France (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Germany (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Greece (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Hong Kong (OTC Healthcare |
2011 | 350,00$ |
Vitamins and Minerals Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Hungary (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in India (OTC Healthcare). T |
2011 | 350,00$ |
Vitamins and Minerals Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Indonesia (OTC Healthcare |
2011 | 350,00$ |
Vitamins and Minerals Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Ireland (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Israel (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Mexico (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in the Netherlands (OTC Heal |
2011 | 350,00$ |
Vitamins and Minerals Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Nigeria (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Pakistan (OTC Healthcare) |
2011 | 350,00$ |
Vitamins and Minerals Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Romania (OTC Healthcare). |
2011 | 350,00$ |
Vitamins and Minerals Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Singapore (OTC Healthcare |
2011 | 350,00$ |
Vitamins and Minerals Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Slovenia (OTC Healthcare) |
2011 | 350,00$ |
Vitamins and Minerals Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in South Africa (OTC Healthc |
2011 | 350,00$ |
Vitamins and Minerals Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in South Korea (OTC Healthca |
2011 | 350,00$ |
Vitamins and Minerals Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Spain (OTC Healthcare). T |
2011 | 350,00$ |
Vitamins and Minerals Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Venezuela (OTC Healthcare |
2011 | 350,00$ |
Vitamins and Minerals Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Vietnam (OTC Healthcare). |
2011 | 350,00$ |
Analgesics Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Asia-Pacific (OTC Healthcare). This |
2011 | 350,00$ |
Analgesics Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Eastern Europe (OTC Healthcare). Thi |
2011 | 350,00$ |
Analgesics Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Latin America (OTC Healthcare). This |
2011 | 350,00$ |
Analgesics Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Middle East and Africa (OTC Healthca |
2011 | 350,00$ |
Analgesics Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in North America (OTC Healthcare). This |
2011 | 350,00$ |
Analgesics Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Western Europe (OTC Healthcare). Thi |
2011 | 350,00$ |
Analgesics Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Argentina (OTC Healthcare). This rep |
2011 | 350,00$ |
Analgesics Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Austria (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Belgium (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Brazil (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Bulgaria (OTC Healthcare). This repo |
2011 | 350,00$ |
Analgesics Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in China (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Croatia (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Denmark (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Egypt (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Finland (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in France (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Germany (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Greece (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Hong Kong (OTC Healthcare). This rep |
2011 | 350,00$ |
Analgesics Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Hungary (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in India (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Indonesia (OTC Healthcare). This rep |
2011 | 350,00$ |
Analgesics Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Ireland (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Israel (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Mexico (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in the Netherlands (OTC Healthcare). Th |
2011 | 350,00$ |
Analgesics Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Nigeria (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Pakistan (OTC Healthcare). This repo |
2011 | 350,00$ |
Analgesics Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Romania (OTC Healthcare). This repor |
2011 | 350,00$ |
Analgesics Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Singapore (OTC Healthcare). This rep |
2011 | 350,00$ |
Analgesics Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Slovenia (OTC Healthcare). This repo |
2011 | 350,00$ |
Analgesics Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in South Africa (OTC Healthcare). This |
2011 | 350,00$ |
Analgesics Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in South Korea (OTC Healthcare). This r |
2011 | 350,00$ |
Analgesics Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Spain (OTC Healthcare). This report |
2011 | 350,00$ |
Analgesics Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Venezuela (OTC Healthcare). This rep |
2011 | 350,00$ |
Analgesics Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Analgesics Market in Vietnam (OTC Healthcare). This repor |
2011 | 350,00$ |
Cough and Cold Preparations Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Asia-Pacific (OTC H |
2011 | 350,00$ |
Cough and Cold Preparations Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Eastern Europe (OTC |
2011 | 350,00$ |
Cough and Cold Preparations Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Latin America (OTC |
2011 | 350,00$ |
Cough and Cold Preparations Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Middle East and Afr |
2011 | 350,00$ |
Cough and Cold Preparations Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in North America (OTC |
2011 | 350,00$ |
Cough and Cold Preparations Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Western Europe (OTC |
2011 | 350,00$ |
Cough and Cold Preparations Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Argentina (OTC Heal |
2011 | 350,00$ |
Cough and Cold Preparations Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Austria (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Belgium (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Brazil (OTC Healthc |
2011 | 350,00$ |
Cough and Cold Preparations Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Bulgaria (OTC Healt |
2011 | 350,00$ |
Cough and Cold Preparations Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in China (OTC Healthca |
2011 | 350,00$ |
Cough and Cold Preparations Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Croatia (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Denmark (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Egypt (OTC Healthca |
2011 | 350,00$ |
Cough and Cold Preparations Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Finland (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in France (OTC Healthc |
2011 | 350,00$ |
Cough and Cold Preparations Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Germany (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Greece (OTC Healthc |
2011 | 350,00$ |
Cough and Cold Preparations Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Hong Kong (OTC Heal |
2011 | 350,00$ |
Cough and Cold Preparations Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Hungary (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in India (OTC Healthca |
2011 | 350,00$ |
Cough and Cold Preparations Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Indonesia (OTC Heal |
2011 | 350,00$ |
Cough and Cold Preparations Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Ireland (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Israel (OTC Healthc |
2011 | 350,00$ |
Cough and Cold Preparations Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Mexico (OTC Healthc |
2011 | 350,00$ |
Cough and Cold Preparations Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in the Netherlands (OT |
2011 | 350,00$ |
Cough and Cold Preparations Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Nigeria (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Pakistan (OTC Healt |
2011 | 350,00$ |
Cough and Cold Preparations Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Romania (OTC Health |
2011 | 350,00$ |
Cough and Cold Preparations Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Singapore (OTC Heal |
2011 | 350,00$ |
Cough and Cold Preparations Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Slovenia (OTC Healt |
2011 | 350,00$ |
Cough and Cold Preparations Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in South Africa (OTC H |
2011 | 350,00$ |
Cough and Cold Preparations Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in South Korea (OTC He |
2011 | 350,00$ |
Cough and Cold Preparations Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Spain (OTC Healthca |
2011 | 350,00$ |
Cough and Cold Preparations Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Venezuela (OTC Heal |
2011 | 350,00$ |
Cough and Cold Preparations Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Vietnam (OTC Health |
2011 | 350,00$ |
First Aid Kits Market in Asia-Pacific to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Asia-Pacific (OTC Healthcare). T |
2011 | 350,00$ |
First Aid Kits Market in Eastern Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Eastern Europe (OTC Healthcare). |
2011 | 350,00$ |
First Aid Kits Market in Latin America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Latin America (OTC Healthcare). |
2011 | 350,00$ |
First Aid Kits Market in Middle East and Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Middle East and Africa (OTC Heal |
2011 | 350,00$ |
First Aid Kits Market in North America to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in North America (OTC Healthcare). |
2011 | 350,00$ |
First Aid Kits Market in Western Europe to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Western Europe (OTC Healthcare). |
2011 | 350,00$ |
First Aid Kits Market in Argentina to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Argentina (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Austria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Austria (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Belgium to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Belgium (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Brazil to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Brazil (OTC Healthcare). This re |
2011 | 350,00$ |
First Aid Kits Market in Bulgaria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Bulgaria (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in China to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in China (OTC Healthcare). This rep |
2011 | 350,00$ |
First Aid Kits Market in Croatia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Croatia (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Denmark to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Denmark (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Egypt to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Egypt (OTC Healthcare). This rep |
2011 | 350,00$ |
First Aid Kits Market in Finland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Finland (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in France to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in France (OTC Healthcare). This re |
2011 | 350,00$ |
First Aid Kits Market in Germany to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Germany (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Greece to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Greece (OTC Healthcare). This re |
2011 | 350,00$ |
First Aid Kits Market in Hong Kong to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Hong Kong (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Hungary to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Hungary (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in India to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in India (OTC Healthcare). This rep |
2011 | 350,00$ |
First Aid Kits Market in Indonesia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Indonesia (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Ireland to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Ireland (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Israel to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Israel (OTC Healthcare). This re |
2011 | 350,00$ |
First Aid Kits Market in Mexico to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Mexico (OTC Healthcare). This re |
2011 | 350,00$ |
Life Sciences Industry IT Spending Forecast in Argentina to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Australia to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Brazil to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Canada to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in China to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in France to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Germany to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in India to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Italy to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Japan to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Mexico to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Middle East and Africa to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Russia to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in South Korea to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in Spain to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in the UK to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
Life Sciences Industry IT Spending Forecast in the US to 2015IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug |
2010 | 995,00$ |
First Aid Kits Market in Nigeria to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Nigeria (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Pakistan to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Pakistan (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Romania to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Romania (OTC Healthcare). This r |
2011 | 350,00$ |
First Aid Kits Market in Singapore to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Singapore (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Slovenia to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Slovenia (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in South Africa to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in South Africa (OTC Healthcare). T |
2011 | 350,00$ |
First Aid Kits Market in South Korea to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in South Korea (OTC Healthcare). Th |
2011 | 350,00$ |
First Aid Kits Market in Spain to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Spain (OTC Healthcare). This rep |
2011 | 350,00$ |
First Aid Kits Market in the Netherlands to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in the Netherlands (OTC Healthcare) |
2011 | 350,00$ |
First Aid Kits Market in Venezuela to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Venezuela (OTC Healthcare). This |
2011 | 350,00$ |
First Aid Kits Market in Vietnam to 2014 (OTC Healthcare)Introduction / / This databook provides key data and information on the First Aid Kits Market in Vietnam (OTC Healthcare). This r |
2011 | 350,00$ |
Global Top 10 Pharmaceutical - Industry, Financial and SWOT AnalysisDatamonitor's Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. T |
2011 | 1.895,00$ |
Allergic Rhinitis Market ForecastIntroduction / / Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a dec |
2010 | 15.200,00$ |
Alzheimer's Disease Market ForecastIntroduction / / Current management of Alzheimer’s disease is wholly inadequate, providing only symptomatic benefit to patients i |
2010 | 15.200,00$ |
Brief: Hepatitis C/AASLD 2010Introduction / / Data from Phase III studies for Vertex/Johnson & Johnson’s telaprevir and Merck & Co’s boceprevir were the main |
2010 | 500,00$ |
Parkinson's Disease Market ForecastIntroduction / / In 2009, the Parkinson’s disease market generated $2.2bn across the seven major markets. As the market approache |
2010 | 15.200,00$ |
Pneumococcal and Meningococcal Vaccines: Market ForecastIntroduction / / Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that cou |
2010 | 15.200,00$ |
Psoriasis Market ForecastIntroduction / / In this report, Datamonitor assesses the main events which shaped the psoriasis market in the past five years, a |
2010 | 15.200,00$ |
Rheumatoid Arthritis Market ForecastIntroduction / / In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF |
2010 | 15.200,00$ |
Schizophrenia Market ForecastIntroduction / / Despite imminent generic erosion of blockbuster brands, the schizophrenia market will retain its value, supporte |
2010 | 15.200,00$ |
Urinary Incontinence Market ForecastIntroduction / / The urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new p |
2010 | 15.200,00$ |
Depression Market ForecastIntroduction / / Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in |
2010 | 15.200,00$ |
Epidemiology: Alzheimer's DiseaseIntroduction / / An estimated 35.6 million people worldwide will be living with dementia in 2010. The number of patients with dem |
2010 | 5.700,00$ |
Epidemiology: Breast CancerIntroduction / Breast cancer will continue to be a major cancer among women in the seven major healthcare markets during the fore |
2010 | 5.700,00$ |
Epidemiology: DepressionIntroduction / / Depression is a very prevalent disease in the seven major markets (the US, Japan, France, Germany, Italy, Spain, |
2010 | 5.700,00$ |
Epidemiology: DyslipidemiaIntroduction / / The large numbers of adults with dyslipidemia in the seven major markets countries can be directly attributed to |
2010 | 5.700,00$ |
Epidemiology: Gastric CancerIntroduction / / Since the 1950s, the incidence of gastric cancer has been declining in the seven major pharmaceutical markets (U |
2010 | 5.700,00$ |
Epidemiology: Hepatocellular CancerIntroduction / / Datamonitor estimates that 88,300 incident cases of hepatocellular cancer will occur in the seven major markets |
2010 | 5.700,00$ |
Epidemiology: Ovarian CancerIntroduction / / Incident cases of ovarian cancer will increase across the seven major healthcare markets between 2010 and 2019. |
2010 | 5.700,00$ |
Epidemiology: Type 1 DiabetesIntroduction / / Due to an increasing incidence of type 1 diabetes in France, Germany, Italy, Spain, and the UK and a steady inci |
2010 | 5.700,00$ |
Epidemiology: Type 2 DiabetesIntroduction / / Type 2 diabetes can be easily managed with a healthy lifestyle, especially related to diet, exercise, and weight |
2010 | 5.700,00$ |
European Healthcare Vertical Market Map 2010Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust |
2010 | 10.000,00$ |
Gilead Sciences: PharmaVitae ProfileIntroduction / This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Takeda Pharmaceutical Co., Ltd: PharmaVitae ProfileIntroduction / This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Astellas Pharma Inc.: PharmaVitae ProfileIntroduction / This analysis examines the historical and forecast performance for Astellas in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Merck KGaA: PharmaVitae ProfileIntroduction / This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical se |
2010 | 5.700,00$ |
Biogen Idec Inc.: PharmaVitae ProfileIntroduction / This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical s |
2010 | 5.700,00$ |
Monoclonal Antibodies: 2010Introduction / Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest |
2010 | 7.600,00$ |
Generics Market Outlook: 2015Introduction / Historical and forecast analysis of the entire generics industry from 2005 through to 2015. Strategic dynamics with |
2010 | 7.600,00$ |
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive marketIntroduction / While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Ava |
2010 | 15.200,00$ |
OTC Healthcare in Asia Pacific - Product Launch QuarterlyIntroduction / / Datamonitor’s OTC Healthcare in Asia Pacific – Product Launch Quarterly provides a complete guide to new product |
2010 | 1.295,00$ |
OTC Healthcare in Eastern Europe - Product Launch QuarterlyIntroduction / / Datamonitor’s OTC Healthcare in Eastern Europe – Product Launch Quarterly provides a complete guide to new produ |
2010 | 1.295,00$ |
OTC Healthcare in Latin America - Product Launch QuarterlyIntroduction / / Datamonitor’s OTC Healthcare in Latin America – Product Launch Quarterly provides a complete guide to new produc |
2010 | 1.295,00$ |
OTC Healthcare in North America - Product Launch QuarterlyIntroduction / / Datamonitor’s OTC Healthcare in North America – Product Launch Quarterly provides a complete guide to new produc |
2010 | 1.295,00$ |
OTC Healthcare in Western Europe - Product Launch QuarterlyIntroduction / / Datamonitor’s OTC Healthcare in Western Europe – Product Launch Quarterly provides a complete guide to new produ |
2010 | 1.295,00$ |
Commercial Insight Top 20 cancer therapy brands forecastIntroduction / / The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy |
2010 | 15.200,00$ |
Asthma/COPD Market ForecastIntroduction / / This model contains a 10 year country, indication, and device specific forecasts for individual products used in |
2010 | 15.200,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in LatviaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in MalaysiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in New ZealandIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in NigeriaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in NorwayIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in PakistanIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in PeruIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in PolandIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in PortugalIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in Republic of KoreaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in RomaniaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in RussiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in Saudi ArabiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SingaporeIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SlovakiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SloveniaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in South AfricaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SpainIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SwedenIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in SwitzerlandIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in TaiwanIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in ThailandIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in the NetherlandsIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in the PhilippinesIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in the USIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in TurkeyIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in UkraineIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in United Arab EmiratesIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in UruguayIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in VenezuelaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in VietnamIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2010 | 495,00$ |
Weight Management Trends & Behaviors: Beyond Dieting & ObesityDetailed insights and analysis on the drivers and inhibitors of weight management. Includes strategic conclusions and actionable r |
2010 | 3.450,00$ |
Global Top 10 Health Care Equipment Companies - Industry, Financial and SWOT AnalysisGlobal Top 10 Health Care Equipment Companies: Industry, Financial and SWOT Analysis / / Datamonitor's Global Top 10 Health Care |
2010 | 1.895,00$ |
Hormone Replacement Therapy For Menopausal Symptoms Market ForecastIntroduction / / Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as |
2010 | 15.200,00$ |
Testosterone Replacement Therapy Market ForecastIntroduction / / The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% fr |
2010 | 15.200,00$ |
Antidiabetics market forecastIntroduction / / Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januv |
2010 | 15.400,00$ |
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipelineDescription of the competitive landscape in antidiabetics across seven major markets with market definition and overviewEvent-driv |
2010 | 15.200,00$ |
Generics: Global Industry GuideDatamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics indus |
2010 | 1.495,00$ |
Eli Lilly & Co.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector. |
2010 | 5.700,00$ |
Johnson & Johnson: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The |
2010 | 5.700,00$ |
AstraZeneca plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. |
2010 | 5.700,00$ |
Amgen Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Bayer Schering Pharma AG: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma se |
2010 | 5.700,00$ |
F. Hoffmann-La Roche Ltd.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Genzyme Corporation: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se |
2010 | 5.700,00$ |
Merck & Co. Inc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. |
2010 | 5.700,00$ |
Pfizer Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Sanofi-Aventis: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector. |
2010 | 5.700,00$ |
OTC Healthcare in Belgium to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Belgium. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Croatia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Croatia. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Nigeria to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Nigeria. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Pakistan to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Pakistan. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in Saudi Arabia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Saudi Arabia. This report is a c |
2009 | 495,00$ |
Inflammatory Bowel Disease Market ForecastQuantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
/ Understand IBD |
2010 | 15.200,00$ |
Osteoporosis Market ForecastIntroduction / / Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching |
2010 | 15.200,00$ |
Menarini: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. T |
2010 | 5.700,00$ |
Merck KGaA: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. |
2010 | 5.700,00$ |
Actelion Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Actelion in the Rx pharmaceutical sector. Th |
2010 | 5.700,00$ |
Nycomed S.C.A. SICAR: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical se |
2010 | 5.700,00$ |
Sandoz International GmbH: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Forest Laboratories Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Biogen Idec Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector |
2010 | 5.700,00$ |
Mylan Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Celgene Corporation: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical se |
2010 | 5.700,00$ |
UCB S.A.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Shire plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Cephalon Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. T |
2010 | 5.700,00$ |
Alcon Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
Watson Pharmaceuticals Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Benchmarking the Pharmaceutical Market by Drug Delivery to 2014Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companiesProvides |
2009 | 7.600,00$ |
Pet Health Care in Russia to 2013Introduction / / This databook provides key data and information on the pet health care market in Russia. This report is a compre |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in FinlandIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in FranceIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in GermanyIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in GreeceIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in Hong KongIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in HungaryIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in IndiaIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in IndonesiaIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in IrelandIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in IsraelIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in ItalyIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in JapanIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in LithuaniaIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in MexicoIntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist |
2010 | 495,00$ |
Top 10 Companies in Canada Healthcare Industry: IT Spending Predictor 2010IntroductionThis databook provides estimates of IT spending for the top 10 companies in the Canadian Healthcare industry. The data |
2010 | 795,00$ |
Top 10 Companies in Canada Life Sciences Industry: IT Spending Predictor 2010IntroductionThis databook provides estimates of IT spending for the top 10 companies in the Canadian Life sciences industry. The d |
2010 | 795,00$ |
Top 10 Companies in the US Healthcare Industry: IT Spending Predictor 2010IntroductionThis databook provides estimates of IT spending for the top 10 companies in the US Healthcare industry. The databook i |
2010 | 795,00$ |
Top 10 Companies in the US Life Sciences Industry: IT Spending Predictor 2010IntroductionThis databook provides estimates of IT spending for the top 10 companies in the US Life sciences industry. The databoo |
2010 | 795,00$ |
Cancer Targeted Therapies and Immunotherapies Market ForecastIntroductionThe oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies t |
2010 | 15.200,00$ |
Moderate to Severe Chronic Nociceptive Pain Market ForecastIntroductionThe moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-r |
2010 | 15.200,00$ |
Antidyslipidemics Market ForecastIntroductionThe antidyslipidemic market is approaching further genericization when in 2011, leading statin brand Lipitor will lose |
2010 | 15.200,00$ |
Insomnia Market ForecastIntroductionThe availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intens |
2010 | 15.200,00$ |
Industry Solutions Guide: Selecting an Ambulatory EHR Vendor in the Healthcare Market (Competitor Focus)IntroductionThis report provides a comparative analysis of the leading ambulatory EHR vendors in the healthcare technology market |
2010 | 3.395,00$ |
Antihormonal Therapies Market ForecastIntroduction Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prosta |
2010 | 15.200,00$ |
Bristol-Myers Squibb Co.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Health Care Equipment & Supplies: Global Industry GuideDatamonitor's Health Care Equipment & Supplies: Global Industry Guide is an essential resource for top-level data and analysis cov |
2010 | 1.495,00$ |
Daiichi Sankyo Co., Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical secto |
2010 | 5.700,00$ |
Takeda Pharmaceutical Co. Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sec |
2010 | 5.700,00$ |
Boehringer Ingelheim GmbH: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical |
2010 | 5.700,00$ |
Genzyme Corporation: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se |
2010 | 5.700,00$ |
Mitsubishi Tanabe Pharma Corporation: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The |
2010 | 5.700,00$ |
Multiple Sclerosis Market ForecastIntroduction / / With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladri |
2010 | 15.200,00$ |
Eisai Co. Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sect |
2010 | 5.700,00$ |
OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry GuideDatamonitor's OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guid |
2010 | 995,00$ |
Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry GuideDatamonitor's Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide is |
2010 | 995,00$ |
Cytotoxic Therapies Market ForecastIntroduction / / Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster produ |
2010 | 15.200,00$ |
OTC Healthcare in Argentina to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Argentina. This report is a comp |
2010 | 495,00$ |
OTC Healthcare in Austria to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Austria. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Belgium to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Belgium. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Brazil to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Brazil. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Bulgaria to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Bulgaria. This report is a compr |
2010 | 495,00$ |
OTC Healthcare in China to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in China. This report is a comprehe |
2010 | 495,00$ |
OTC Healthcare in Croatia to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Croatia. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Denmark to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Denmark. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Egypt to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Egypt. This report is a comprehe |
2010 | 495,00$ |
OTC Healthcare in Finland to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Finland. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in France to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in France. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Germany to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Germany. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Greece to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Greece. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Hong Kong to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Hong Kong. This report is a comp |
2010 | 495,00$ |
OTC Healthcare in Hungary to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Hungary. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in India to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in India. This report is a comprehe |
2010 | 495,00$ |
OTC Healthcare in Indonesia to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Indonesia. This report is a comp |
2010 | 495,00$ |
OTC Healthcare in Ireland to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Ireland. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Israel to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Israel. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Japan to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Japan. This report is a comprehe |
2010 | 495,00$ |
OTC Healthcare in Malaysia to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Malaysia. This report is a compr |
2010 | 495,00$ |
OTC Healthcare in Mexico to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Mexico. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Nigeria to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Nigeria. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Pakistan to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Pakistan. This report is a compr |
2010 | 495,00$ |
OTC Healthcare in Romania to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Romania. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Saudi Arabia to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Saudi Arabia. This report is a c |
2010 | 495,00$ |
OTC Healthcare in Singapore to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Singapore. This report is a comp |
2010 | 495,00$ |
OTC Healthcare in Slovenia to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Slovenia. This report is a compr |
2010 | 495,00$ |
OTC Healthcare in South Africa to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in South Africa. This report is a c |
2010 | 495,00$ |
OTC Healthcare in South Korea to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in South Korea. This report is a co |
2010 | 495,00$ |
OTC Healthcare in Spain to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Spain. This report is a comprehe |
2010 | 495,00$ |
OTC Healthcare in Sweden to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Sweden. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Switzerland to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Switzerland. This report is a co |
2010 | 495,00$ |
OTC Healthcare in Taiwan to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Taiwan. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in Thailand to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Thailand. This report is a compr |
2010 | 495,00$ |
OTC Healthcare in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the ice cream market in four emerging / high growth economies: Brazil, Russia, |
2010 | 1.995,00$ |
OTC Healthcare in the Netherlands to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in the Netherlands. This report is |
2010 | 495,00$ |
OTC Healthcare in the Philippines to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in the Philippines. This report is |
2010 | 495,00$ |
OTC Healthcare in the UK to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in the UK. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in the US to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in the US. This report is a compreh |
2010 | 495,00$ |
OTC Healthcare in United Arab Emirates to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in United Arab Emirates. This repor |
2010 | 495,00$ |
OTC Healthcare in Uruguay to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Uruguay. This report is a compre |
2010 | 495,00$ |
OTC Healthcare in Venezuela to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Venezuela. This report is a comp |
2010 | 495,00$ |
OTC Healthcare in Vietnam to 2014Introduction / / This databook provides key data and information on the OTC healthcare market in Vietnam. This report is a compre |
2010 | 495,00$ |
Other OTC Healthcare Products in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the other OTC healthcare products market in four emerging / high growth econom |
2010 | 1.995,00$ |
Topical OTC Medicines in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the topical OTC medicines market in four emerging / high growth economies: Bra |
2010 | 1.995,00$ |
Hepatitis B Market ForecastIntroduction / / This model contains a ten year commercial forecast of hepatitis B drug sales by country, class, molecule and bra |
2010 | 15.200,00$ |
HIV Market ForecastIntroduction / / In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10 |
2010 | 15.200,00$ |
Migraine Market ForecastIntroduction / / After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in |
2010 | 15.200,00$ |
Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmissionIntroduction / / Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious compl |
2010 | 3.800,00$ |
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapyIntroduction / / Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ov |
2010 | 3.800,00$ |
Analgesics in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the analgesics market in four emerging / high growth economies: Brazil, Russia |
2010 | 1.995,00$ |
Cough and Cold Preparations in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the cough and cold preparations market in four emerging / high growth economie |
2010 | 1.995,00$ |
First Aid Kits in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the first aid kits market in four emerging / high growth economies: Brazil, Ru |
2010 | 1.995,00$ |
Indigestion Preparations in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the indigestion preparations market in four emerging / high growth economies: |
2010 | 1.995,00$ |
Plasters & Bandages in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the plasters & bandages market in four emerging / high growth economies: Brazi |
2010 | 1.995,00$ |
Traditional Medicines in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014Introduction / / This report covers key aspects of the traditional medicines market in four emerging / high growth economies: Bra |
2010 | 1.995,00$ |
Global OTC Healthcare Market to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering 60 countries across the Gl |
2010 | 495,00$ |
OTC Healthcare in Asia-Pacific to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering 15 countries in the Asia-P |
2010 | 495,00$ |
OTC Healthcare in Eastern Europe to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering 11 countries in Eastern Eu |
2010 | 495,00$ |
OTC Healthcare in Latin America to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering eight countries in Latin A |
2010 | 495,00$ |
OTC Healthcare in Middle East and Africa to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering seven countries in the Mid |
2010 | 495,00$ |
OTC Healthcare in North America to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering two countries in North Ame |
2010 | 495,00$ |
OTC Healthcare in Western Europe to 2014Introduction / / This databook provides key data and information on the OTC healthcare market covering 17 countries in Western Eu |
2010 | 495,00$ |
OTC Healthcare Market - Regional level to 2014Introduction / / This databook provides key data and information on the OTC healthcare market for the following regions: Asia-Pac |
2010 | 495,00$ |
Novartis AG: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. T |
2010 | 5.700,00$ |
Global Top 10 Healthcare Equipment Companies - Industry, Financial and SWOT AnalysisPerformance of the global healthcare equipment market on the basis of sales, volume and respective growth patterns over the past f |
2010 | 1.895,00$ |
GlaxoSmithKline plc: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector |
2010 | 5.700,00$ |
Healthcare Providers Guide to Telehealth (Best Practice Insights)Identifies the benefits telehealthDifferentiates between the types of telehealth technologiesProvides guidance on how to start a t |
2010 | 1.895,00$ |
Opioids in Australia Market ForecastIntroduction / / The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the |
2010 | 5.700,00$ |
Global Top 10 Pharmaceutical Companies - Industry, Financial and SWOT AnalysisPerformance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five ye |
2009 | 1.895,00$ |
OTC Healthcare in Latin America to 2013Introduction / / This databook provides key data and information on the OTC healthcare market covering eight countries in Latin A |
2010 | 495,00$ |
Asthma/COPD in Australia Market ForecastIntroduction
/
/ The Australian asthma/COPD market grew from $278m in 2006 to $333m in 2009. Its growth will slow considerably |
2010 | 5.700,00$ |
Pharmaceutical Logistics Spending in Belgium to 2013Introduction / / Pharmaceutical Logistics Spending in Belgium to 2013 provides a comprehensive analysis of the logistics spending |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in France to 2013Introduction / / Pharmaceutical Logistics Spending in France to 2013 provides a comprehensive analysis of the logistics spending |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in Germany to 2013Introduction / / Pharmaceutical Logistics Spending in Germany to 2013 provides a comprehensive analysis of the logistics spending |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in Italy to 2013Introduction / / Pharmaceutical Logistics Spending in Italy to 2013 provides a comprehensive analysis of the logistics spending i |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in Spain to 2013Introduction / / Pharmaceutical Logistics Spending in Spain to 2013 provides a comprehensive analysis of the logistics spending i |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in Sweden to 2013Introduction / / Pharmaceutical Logistics Spending in Sweden to 2013 provides a comprehensive analysis of the logistics spending |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in the Netherlands to 2013Introduction / / Pharmaceutical Logistics Spending in the Netherlands to 2013 provides a comprehensive analysis of the logistics |
2010 | 995,00$ |
Pharmaceutical Logistics Spending in the UK to 2013Introduction / / Pharmaceutical Logistics Spending in the UK to 2013 provides a comprehensive analysis of the logistics spending |
2010 | 995,00$ |
Global Top 10 Biotechnology Companies Industry, Financial and SWOT AnalysisPerformance of the global biotechnology market on the basis of sales, volume and respective growth patterns over the past five yea |
2009 | 1.895,00$ |
Global Top 10 Chemical Companies Industry, Financial and SWOT AnalysisPerformance of the global chemicals market on the basis of sales, volume and respective growth patterns over the past five yearsOb |
2009 | 1.895,00$ |
Company Financials: Geron CorporationIntroductionThe Company Financials offers insights into the financial performance of the company over last five years for about 10 |
2010 | 75,00$ |
Pharmaceuticals: Global Industry OverviewDatamonitor's Pharmaceuticals: Global Industry Overview is an essential resource for top-level data and analysis covering the Glob |
2010 | 1.495,00$ |
Top 20 Cancer Therapy Brands in Australia ForecastIntroduction / / The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% sin |
2010 | 5.700,00$ |
Cloud Computing Adoption In The APAC Life Sciences IndustryEvaluates the responses of a total of 50 life sciences companies from India, China, and Japan.Discusses which types of companies a |
2010 | 3.395,00$ |
2010 Guide to the Life Sciences Industry for Technology ProvidersOffers an overview of the pharmaceutical and biotechnology sectorsDiscusses key areas where there is greatest need for technology |
2010 | 1.895,00$ |
OTC Healthcare in Asia-Pacific to 2013Introduction / / This databook provides key data and information on the OTC healthcare market covering 15 countries in the Asia-P |
2009 | 495,00$ |
OTC Healthcare in Australia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Australia. This report is a comp |
2009 | 495,00$ |
OTC Healthcare in Austria to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Austria. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Brazil to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Brazil. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Canada to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Canada. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Chile to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Chile. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in China to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in China. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Colombia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Colombia. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in Denmark to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Denmark. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Eastern Europe to 2013Introduction / / This databook provides key data and information on the OTC healthcare market covering 11 countries in Eastern Eu |
2009 | 495,00$ |
OTC Healthcare in Egypt to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Egypt. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Germany to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Germany. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Greece to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Greece. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Hong Kong to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Hong Kong. This report is a comp |
2009 | 495,00$ |
OTC Healthcare in Hungary to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Hungary. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in India to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in India. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Indonesia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Indonesia. This report is a comp |
2009 | 495,00$ |
OTC Healthcare in Ireland to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Ireland. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Italy to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Italy. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Japan to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Japan. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Mexico to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Mexico. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Morocco to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Morocco. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in New Zealand to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in New Zealand. This report is a co |
2009 | 495,00$ |
OTC Healthcare in Portugal to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Portugal. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in Russia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Russia. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Slovenia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Slovenia. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in Sweden to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Sweden. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Switzerland to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Switzerland. This report is a co |
2009 | 495,00$ |
OTC Healthcare in Taiwan to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Taiwan. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in the Netherlands to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in the Netherlands. This report is |
2009 | 495,00$ |
OTC Healthcare in the Philippines to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in the Philippines. This report is |
2009 | 495,00$ |
OTC Healthcare in the UK to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in the UK. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in the US to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in the US. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Turkey to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Turkey. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Ukraine to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Ukraine. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Uruguay to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Uruguay. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Vietnam to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Vietnam. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in Western Europe to 2013Introduction / / This databook provides key data and information on the OTC healthcare market covering 17 countries in Western Eu |
2009 | 495,00$ |
OTC Healthcare Market - Regional level to 2013Introduction / / This databook provides key data and information on the OTC healthcare market for the following regions: Asia-Pac |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in ArgentinaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in BrazilIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in CanadaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in ChileIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in ColombiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in EgyptIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in MalaysiaIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in Saudi ArabiaIntroduction / / Datamonitor's retail databooks are based on key market value data for 8 major product sectors, 16 retail distrib |
2009 | 495,00$ |
Drug Stores and Health and Beauty Stores (including Pharmacies) in United Arab EmiratesIntroduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai |
2009 | 495,00$ |
OTC Healthcare in Finland to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Finland. This report is a compre |
2009 | 495,00$ |
OTC Healthcare in France to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in France. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Malaysia to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Malaysia. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in North America to 2013Introduction / / This databook provides key data and information on the OTC healthcare market covering two countries in North Ame |
2009 | 495,00$ |
OTC Healthcare in Norway to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Norway. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Poland to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Poland. This report is a compreh |
2009 | 495,00$ |
OTC Healthcare in Singapore to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Singapore. This report is a comp |
2009 | 495,00$ |
OTC Healthcare in South Africa to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in South Africa. This report is a c |
2009 | 495,00$ |
OTC Healthcare in South Korea to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in South Korea. This report is a co |
2009 | 495,00$ |
OTC Healthcare in Spain to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Spain. This report is a comprehe |
2009 | 495,00$ |
OTC Healthcare in Thailand to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in Thailand. This report is a compr |
2009 | 495,00$ |
OTC Healthcare in the Czech Republic to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in the Czech Republic. This report |
2009 | 495,00$ |
OTC Healthcare in United Arab Emirates to 2013Introduction / / This databook provides key data and information on the OTC healthcare market in United Arab Emirates. This repor |
2009 | 495,00$ |
Pharmaceuticals: Asia-Pacific Industry GuideDatamonitor's Pharmaceuticals: Asia-Pacific Industry Guide is an essential resource for top-level data and analysis covering the A |
2010 | 995,00$ |
Pharmaceuticals: Belgium Industry GuideDatamonitor's Pharmaceuticals: Belgium Industry Guide is an essential resource for top-level data and analysis covering the Belgiu |
2010 | 995,00$ |
Pharmaceuticals: Canada Industry GuideDatamonitor's Pharmaceuticals: Canada Industry Guide is an essential resource for top-level data and analysis covering the Canada |
2010 | 995,00$ |
Pharmaceuticals: China Industry GuideDatamonitor's Pharmaceuticals: China Industry Guide is an essential resource for top-level data and analysis covering the China Ph |
2010 | 995,00$ |
Pharmaceuticals: Europe Industry GuideDatamonitor's Pharmaceuticals: Europe Industry Guide is an essential resource for top-level data and analysis covering the Europe |
2010 | 995,00$ |
Pharmaceuticals: France Industry GuideDatamonitor's Pharmaceuticals: France Industry Guide is an essential resource for top-level data and analysis covering the France |
2010 | 995,00$ |
Pharmaceuticals: Germany Industry GuideDatamonitor's Pharmaceuticals: Germany Industry Guide is an essential resource for top-level data and analysis covering the German |
2010 | 995,00$ |
Pharmaceuticals: Italy Industry GuideDatamonitor's Pharmaceuticals: Italy Industry Guide is an essential resource for top-level data and analysis covering the Italy Ph |
2010 | 995,00$ |
Pharmaceuticals: Japan Industry GuideDatamonitor's Pharmaceuticals: Japan Industry Guide is an essential resource for top-level data and analysis covering the Japan Ph |
2010 | 995,00$ |
Pharmaceuticals: Netherlands Industry GuideDatamonitor's Pharmaceuticals: Netherlands Industry Guide is an essential resource for top-level data and analysis covering the Ne |
2010 | 995,00$ |
Pharmaceuticals: Spain Industry GuideDatamonitor's Pharmaceuticals: Spain Industry Guide is an essential resource for top-level data and analysis covering the Spain Ph |
2010 | 995,00$ |
Pharmaceuticals: United Kingdom Industry GuideDatamonitor's Pharmaceuticals: United Kingdom Industry Guide is an essential resource for top-level data and analysis covering the |
2010 | 995,00$ |
Pharmaceuticals: United States Industry GuideDatamonitor's Pharmaceuticals: United States Industry Guide is an essential resource for top-level data and analysis covering the |
2010 | 995,00$ |
Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companiesForecast sales of the therapeutic cancer vaccines in late-phase development in the seven major markets over the period 2009 to 201 |
2009 | 11.400,00$ |
Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis populationSnapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinio |
2009 | 15.200,00$ |
Neuropathic Pain Market ForecastIntroduction / / Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion b |
2009 | 15.200,00$ |
Company Financials: Abbott LaboratoriesIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Acadia Pharmaceuticals Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Achillion Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Acorda Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Actelion LtdIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Adolor CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ADVENTRX Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Affymax, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Alcon, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Alexion Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Alexza PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Alkermes, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Allos Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Alnylam Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Altus Pharmaceuticals Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Amgen, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Amylin Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Anadys Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Anesiva, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: AngioDynamics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Antares Pharma, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Antisoma PLCIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ARCA Biopharma, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Arena Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Arqule, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Array Biopharma Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Aryx Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: AspenBio PharmaIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: AstraZeneca PLCIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Auxilium Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Basilea PharmaceuticaIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Baxter International Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Beckman Coulter, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Becton, Dickinson and CompanyIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Biocryst PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Biogen Idec, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: BioMarin Pharmaceutical IncIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: BioMimetic Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: BIOMS Medicals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Biovail CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Boston Scientific CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Bristol-Myers Squibb CompanyIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: BTG plcIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: C. R. Bard, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cadence PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Candela CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cardiome Pharma CorpIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Carl Ziess Meditec AGIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Celgene CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Celldex Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cephalon, IncIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Chelsea TherapeuticsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cougar Biotechnology, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: CSL LimitedIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cubist Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: CuraGen CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cypress Bioscience, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cytokinetics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Cytori Therapeutics Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Danaher CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Dendreon CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Depomed, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Discovery Laboratories, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: DURECT CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: DUSA Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Dyax CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Edwards Lifesciences CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Elan Corporation, plcIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Eli Lilly and CompanyIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Endo Pharmaceuticals Holdings Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ExelixisIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: F. Hoffmann-La RocheIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Flamel TechnologiesIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Forest Laboratories, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Gedeon Richter PlcIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Genentech, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Genmab A/SIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Genomic HealthIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Genta IncorporatedIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Genzyme CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Gilead Sciences, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: GlaxoSmithKline PlcIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: GTC Biotherapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: GTx, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Halozyme Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Hologic, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Human Genome Sciences, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Idenix Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Illumina, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ImmunoGen, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: IncyteIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Infinity PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Inspire PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: InterMune, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Intuitive SurgicalIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Isis Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ISTA Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Jazz Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Johnson & JohnsonIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Keryx Biopharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Labopharm Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Life Technologies CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Mannkind CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Martek Biosciences CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Maxygen, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: MDRNA, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Medicis Pharmaceutical CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: MedivationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Medtronic, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Merck & Co., Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: MicrometIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Momenta PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: MorphoSys AGIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Nektar TherapeuticsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Neurocrine Biosciences, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Novavax, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: NuVasiveIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Oncogenex Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Optimer Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Orexigen Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: OSI PharmaceuticalsIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Pain Therapeutics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Pfizer Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: POZEN, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Progenics Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Qiagen NVIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: QLT, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Recordati S.p.A.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Regeneron Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Salix Pharmaceuticals, Ltd.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Sangamo Biosciences, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Sanofi-Aventis SAIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Santarus, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Savient Pharmaceuticals Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Schering-Plough CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Seattle Genetics, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: SenoRx, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Shionogi & Co., Ltd.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Smith & Nephew plcIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Spectrum Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: St. Jude Medical, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Stryker CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: SuperGen, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Transcept Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: UCB S.A.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: United Therapeutics CorporationIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Varian Medical Systems, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Vertex Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: ViroPharma IncorporatedIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Warner Chilcott LimitedIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Watson Pharmaceuticals, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: WyethIntroduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Company Financials: Zimmer Holdings, Inc.Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab |
2010 | 75,00$ |
Pet Health Care in India to 2013Introduction / / This databook provides key data and information on the pet health care market in India. This report is a compreh |
2010 | 495,00$ |
Pet Health Care in Latin America to 2013Introduction / / This databook provides key data and information on the pet health care market covering eight countries in Latin |
2010 | 495,00$ |
Pet Health Care in Asia-Pacific to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Australia to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Austria to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Belgium to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Canada to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Colombia to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Denmark to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Eastern Europe to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Egypt to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Finland to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in France to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Germany to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Greece to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Hungary to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Ireland to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Italy to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Japan to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Malaysia to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Middle East and Africa to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in New Zealand to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in North America to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Portugal to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in South Africa to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in South Korea to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Spain to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Sweden to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Switzerland to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Thailand to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in the Czech Republic to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in the Netherlands to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in the UK to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in the US to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care in Western Europe to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pet Health Care Market - Regional level to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Pharmaceutical IT Spending Forecast in Canada to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Canada through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending Forecast in Mexico to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Mexico through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending Forecast in the UK to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in the UK through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending Forecast in the US to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in the US through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending in Australia to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Australia through to 2013 / / *In eac |
2009 | 995,00$ |
Pharmaceutical IT Spending in Brazil to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Brazil through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending in China to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in China through to 2013 / / *In each su |
2009 | 995,00$ |
Pharmaceutical IT Spending in France to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in France through to 2013 / / *In each s |
2009 | 995,00$ |
Pharmaceutical IT Spending in Germany to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Germany through to 2013 / / *In each |
2009 | 995,00$ |
Pharmaceutical IT Spending in India to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in India through to 2013 / / *In each su |
2009 | 995,00$ |
Pharmaceutical IT Spending in Italy to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Italy through to 2013 / / *In each su |
2009 | 995,00$ |
Pharmaceutical IT Spending in Japan to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Japan through to 2013 / / *In each su |
2009 | 995,00$ |
Pharmaceutical IT Spending in South Korea to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in South Korea through to 2013 / / *In e |
2009 | 995,00$ |
Pharmaceutical IT Spending in Spain to 2013Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Spain through to 2013 / / *In each su |
2009 | 995,00$ |
Global Pet Health Care Market to 2013Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp |
2009 | 495,00$ |
Orthopedics: Global Industry GuideDatamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the Orthopedics |
2009 | 995,00$ |
Antibacterials Market ForecastIntroduction / / The antibacterials sector is increasingly shifting towards the hospital sector. In 2019, the fragmenting market |
2009 | 15.200,00$ |
Antithrombotics Market ForecastIntroduction / / The antithrombotics market, comprising anticoagulant and antiplatelet sectors, has grown steadily over the 20040 |
2009 | 15.200,00$ |
Pharmaceutical Company Outlook to 2014Introduction / / PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from |
2009 | 7.600,00$ |
Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatmentIntroduction / / Estimated to affect 6.7 million individuals across the seven major markets in 2009, the population of patients s |
2009 | 15.200,00$ |
Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)Introduction / / The treatment outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients have impr |
2009 | 15.200,00$ |
2009 Pharmaceutical M&A OverviewIntroduction / / After a slump in M&A activity following the global economic downturn and with the looming threat of the 2011 "pa |
2009 | 11.400,00$ |
Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatnessIntroduction / / The development of therapeutic vaccines has expanded beyond cancer indications and is attracting increasing inte |
2009 | 3.800,00$ |
Stakeholder Opinions: Biomarkers in Rheumatology - Awaiting the next step towards personalized medicineIntroduction / / The growing recognition from companies of the applied benefits from biomarkers in rheumatology has spurred comme |
2009 | 3.800,00$ |
Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still neededIntroduction / / Endometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Sy |
2009 | 11.400,00$ |
Big Pharma Mega-Mergers 1995-2014Introduction / / Mega-mergers (defined here as M&A events with deal sizes >$5bn) have been a long-term strategic feature of the p |
2009 | 7.600,00$ |
Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical developmentIntroduction / / Gene therapy looks to be coming of age, with seven projects in Phase III clinical development and one project cu |
2009 | 3.800,00$ |
Boehringer Ingelheim GmbH: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical |
2009 | 5.700,00$ |
Big Pharma Performance Before, During and Beyond the Global RecessionIntroduction / / This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the rec |
2009 | 7.600,00$ |
Supportive Care in Oncology Market ForecastIntroduction / / Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects t |
2009 | 15.200,00$ |
Mapping the Healthcare Landscape Bringing pharmaceuticals into focusIntroduction / / Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from |
2009 | 7.600,00$ |
Monoclonal antibodies: 2009 updateIntroduction / / The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commerci |
2009 | 7.600,00$ |
Emerging Markets Series: Indonesia and PhilippinesIntroduction / / As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long |
2009 | 7.600,00$ |
Antipsychotics Market ForecastIntroduction / / In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market valu |
2009 | 15.200,00$ |
Les Laboratoires Servier: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical se |
2009 | 5.700,00$ |
King Pharmaceuticals Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for King in the prescription pharmaceutical secto |
2009 | 5.700,00$ |
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicineIntroduction / / CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will transl |
2009 | 11.400,00$ |
Antidiabetics in Australia Market ForecastIntroduction / / Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the |
2009 | 5.700,00$ |
Antihypertensives Market ForecastScope |
2009 | 15.200,00$ |
Attention-Deficit Hyperactivity Disorder Market ForecastScope |
2009 | 15.200,00$ |
Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impactScope / / *Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and |
2009 | 15.200,00$ |
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiriesScope / / *Description of the competitive landscape in antihypertensives across seven major markets with market definition and ov |
2009 | 15.200,00$ |
Inflammatory Bowel Disease Market ForecastScope |
2009 | 15.200,00$ |
Molecular Targeted Cancer Therapies Market ForecastScope |
2009 | 15.200,00$ |
New Multi-Marketing Channel StrategiesScope / / *Provides an overview of the reasons behind the need for new marketing channels / / *Explores the different channel mi |
2009 | 3.800,00$ |
Obesity Market ForecastScope |
2009 | 15.200,00$ |
Osteoporosis Market ForecastScope |
2009 | 15.200,00$ |
Pipeline and Commercial Insight: Osteoporosis - Novel agents to battle for payer acceptanceScope / / * Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China). / |
2009 | 15.200,00$ |
Pricing and Reimbursement: Innovative Risk-Sharing StrategiesScope / / *Overview of the different types of risk-sharing agreements adopted by manufacturers / / *Insight into the utilization |
2009 | 3.800,00$ |
Psoriasis Market ForecastScope |
2009 | 15.200,00$ |
Schering-Plough Corporation: PharmaVitae ProfileScope |
2009 | 5.700,00$ |
Seasonal Influenza Vaccines Market ForecastScope |
2009 | 15.200,00$ |
Stakeholder Opinions: Skin and soft tissue infectionsScope / / *Epidemiological trends and economic impact of key pathogens / / *Overview of diagnosis and referral patterns / / *An |
2009 | 3.800,00$ |
Wyeth: PharmaVitae ProfileScope |
2009 | 5.700,00$ |
Allergan Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The |
2009 | 5.700,00$ |
Anticonvulsants Market ForecastIntroduction / / In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therape |
2009 | 15.200,00$ |
Antidepressants Market ForecastIntroduction / / With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to d |
2009 | 15.200,00$ |
Chugai Pharmaceutical Co. Ltd: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sec |
2009 | 5.700,00$ |
Gilead Sciences Inc.: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sec |
2009 | 5.700,00$ |
Hormonal Contraceptives Market ForecastIntroduction / / Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world |
2009 | 15.200,00$ |
Novo Nordisk A/S: PharmaVitae ProfileIntroduction / / This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. |
2009 | 5.700,00$ |
Orphan Drug StrategiesIntroduction / / With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now loo |
2009 | 3.800,00$ |
Parkinson's Disease Market ForecastIntroduction / / The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each dru |
2009 | 15.200,00$ |
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapyIntroduction / / The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based o |
2009 | 15.200,00$ |
Top 20 Cancer Therapy Brands ForecastIntroduction / / The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, |
2009 | 15.200,00$ |
ProductTitle Healthcare Technology Spending Through 2014 (Interactive Model)Understand the opportunity size for technology spending in the global healthcare market
/ Identify potential areas for spending |
2009 | 15.000,00$ |
ProductTitle Future IT Trends and Projects: Healthcare Technology in India (Industry Focus)Highlights future healthcare IT trends and opportunities
/ Analyzes the drivers and barriers of healthcare IT adoption
/ Outline |
2009 | 1.895,00$ |
Celgene Corporation: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile |
2009 | 5.700,00$ |
Healthcare: Global Industry Guideof the Report / / Contains an executive summary and data on value, volume and segmentation for Health Care Equipment, Health Ca |
2009 | 555,00$ |
Johnson & Johnson: PharmaVitae ProfileThis analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encom |
2009 | 5.700,00$ |
Opioids Market ForecastThe opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the |
2009 | 15.200,00$ |
Pharmaceuticals: Global Industry Guideof the Report / / Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pha |
2009 | 740,00$ |
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaosDefining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge / / Transla |
2009 | 3.800,00$ |
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of lifeAn overview of the epidemiological trends in the seven major markets and rest of world / / Discussion of the diagnostic methods f |
2009 | 3.800,00$ |
Bayer Schering Pharma AG: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile |
2009 | 5.700,00$ |
Biogen Idec Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector. The profile enco |
2009 | 5.700,00$ |
Chugai Pharmaceutical Co. Ltd: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile e |
2009 | 5.700,00$ |
Dainippon Sumitomo Pharma Co. Ltd: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Dainippon Sumitomo in the Rx pharma sector. The profile encompa |
2009 | 5.700,00$ |
F. Hoffmann-La Roche Ltd.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile en |
2009 | 5.700,00$ |
Genentech Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompas |
2009 | 5.700,00$ |
GlaxoSmithKline plc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompass |
2009 | 5.700,00$ |
King Pharmaceuticals Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile enc |
2009 | 5.700,00$ |
Les Laboratoires Servier: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile |
2009 | 5.700,00$ |
Merck & Co. Inc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile en |
2009 | 5.700,00$ |
Nicotine Dependence Market ForecastWith a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence |
2009 | 15.200,00$ |
Nycomed A/S: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile |
2009 | 5.700,00$ |
Otsuka Pharmaceutical Group: PharmaVitae ModelThis model contains historical and forecast sales data for Otsuka in the prescription pharmaceutical sector, based on company-repo |
2009 | 5.700,00$ |
Otsuka Pharmaceutical Group: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile e |
2009 | 5.700,00$ |
Pricing and Reimbursement in The United Arab EmiratesOverview of the healthcare reforms undertaken in Abu Dhabi and Dubai in order to contain costs / / Strategic analysis of the chan |
2009 | 3.800,00$ |
Schering-Plough Corporation: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encom |
2009 | 5.700,00$ |
Sepracor Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompa |
2009 | 5.700,00$ |
Shire plc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompa |
2009 | 5.700,00$ |
Solvay S.A.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile e |
2009 | 5.700,00$ |
Stakeholder Opinions: Celiac Disease - Licensing opportunities exist in untapped marketReview of epidemiology, issues with diagnosisboth current techniques and those with future potentialand management of celiac disea |
2009 | 3.800,00$ |
Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and developmentUsage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens / / |
2009 | 3.800,00$ |
Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugsDisease background, segmentation and epidemiology of UTIs in the US, Japan and five major European countries / / Overview of unm |
2009 | 3.800,00$ |
Stakeholder Opinions: Vaccine administration technologies - Beyond needlesIn-depth analysis of key dermal and mucosal vaccine administration technologies / / Thorough assessment of the potential for sele |
2009 | 3.800,00$ |
UCB S.A.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile enco |
2009 | 5.700,00$ |
Wyeth: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile en |
2009 | 5.700,00$ |
Opportunities in Bone & Joint Health: Consumer Attitudes & BehaviorsDetailed insights and analysis documenting the drivers and inhibitors of bone and joint health enhancing food and beverages / / A |
2009 | 3.995,00$ |
Opportunities in Heart Health: Consumer Attitudes & BehaviorsDetailed insights and analysis documenting the drivers and inhibitors of heart health enhancing products / / Analysis documenting |
2009 | 3.995,00$ |
Pharmaceutical IT Spending in India to 2013The databook provides forecasts relating to total pharmaceutical IT spending in India through to 2013
/ In each sub-sector, pharm |
2009 | 995,00$ |
Future Pharmaceutical Industry Trends:Provides key strategies and trends shaping the future of the pharmaceutical industry
/ Examines the impact of the Obama administr |
2009 | 5.700,00$ |
Hepatitis C - Therapy Area Pipeline ReportUnderstand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific ther |
2009 | 1.495,00$ |
Hepatitis B - Therapy Area Pipeline ReportUnderstand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific ther |
2009 | 1.495,00$ |
Evaluating the Use of Superfruits as a Source of Antioxidants to Promote Health and WellnessA conference presentation given by Datamonitor's New Consumer Insight (NCI) team in January 2009 / / This presentation combines c |
2009 | 995,00$ |
PharmaVitae: Company Comparator ToolThe Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you |
2009 | 45.600,00$ |
Pricing and Reimbursement in Key Asia Pacific MarketsInsight into pricing and reimbursement strategies in Australia, Singapore, China and Hong Kong / / Analysis of drivers and barrie |
2009 | 3.800,00$ |
Pharmaceutical Company Outlook to 2013Analysis of the sales outlook for the PharmaVitae universe of leading prescription pharma companies to 2013 / / Assessment of the |
2008 | 7.600,00$ |
Stakeholder Opinions: SarcomasOverview of sarcoma subtypes, epidemiology, potential risk factors, disease staging and diagnosis / / Current treatment options f |
2008 | 3.800,00$ |
Stakeholder Insight: Spondyloarthropathies - Disease perception limits market potentialAnalysis of the results of a survey of 180 rheumatologists and 180 dermatologists supported by key opinion leader interviews / / |
2008 | 15.200,00$ |
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscapeOverview licensing trends up until the credit crisis / / Strategic analysis of biotech's funding crisis / / Insight into how the |
2008 | 3.800,00$ |
Teva Pharmaceutical Industries Ltd: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical sector. The profile enc |
2008 | 5.700,00$ |
Barr Pharmaceuticals Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile enc |
2008 | 5.700,00$ |
Watson Pharmaceuticals Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
Mylan Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile en |
2008 | 5.700,00$ |
Cephalon Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. The profile encompa |
2008 | 5.700,00$ |
Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competitionIn-depth analysis of the current and future rheumatoid arthritis market across the US, 5EU and Japanese markets, and a 'rest of wo |
2008 | 15.200,00$ |
Novartis AG: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompa |
2008 | 5.700,00$ |
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, SarcomasExamination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor type |
2008 | 11.400,00$ |
Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented marketsDescription and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia / / Fragmented healthcare deli |
2008 | 3.800,00$ |
Gilead Sciences Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
H. Lundbeck A/S: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Lundbeck in the prescription pharma global company strategy, po |
2008 | 5.700,00$ |
Sandoz International GmbH: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccinesMarket overview with current market assessment in terms of leading players, brands and geographies / / In-depth analyses of the l |
2008 | 15.200,00$ |
Stakeholder Insight: Infertility - Undifferentiated drugs force need to strengthen prescriber and payer relationshipPatient segmentation including detailed etiology of female and male infertility. / / Analysis of presentation, diagnosis, and tre |
2008 | 15.200,00$ |
Sanofi-Aventis: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector. The profile encomp |
2008 | 5.700,00$ |
Generics: Global Industry GuideContains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe |
2008 | 1.495,00$ |
Biotechnology: Global Industry GuideContains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe |
2008 | 1.495,00$ |
Orthopedics: Global Industry GuideContains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe |
2008 | 1.495,00$ |
Merck & Co. Inc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile en |
2008 | 5.700,00$ |
Forest Laboratories Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
King Pharmaceuticals Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile enc |
2008 | 5.700,00$ |
Stakeholder Insight: Chronic Leukemias - Is there room left for improvement?Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key |
2008 | 15.200,00$ |
Molecular Diagnostics: a primer on an emerging sectorA definitive classification system for in vitro diagnostics (IVD) and molecular diagnostics (MDx), and the differing regulatory pa |
2008 | 7.600,00$ |
Shire plc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompa |
2008 | 5.700,00$ |
Stakeholder Insight: Systemic Lupus Erythematosus Imprecise segmentation complicates treatment algorithmsAnalysis of key marketed brands and late-stage pipeline drugs. / / Anxiety disorders-specific drug sales volume and value forecas |
2008 | 15.200,00$ |
Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugsCurrent diagnosis and treatment of bladder cancer, including treatment regimens by stage and geographical location / / Issues in |
2008 | 3.800,00$ |
Pet Health Care in Switzerland to 2011Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot |
2008 | 495,00$ |
Pet Health Care in the UK to 2011Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot |
2008 | 495,00$ |
Pet Health Care in Slovenia to 2011Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot |
2008 | 495,00$ |
Menarini: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompa |
2008 | 5.700,00$ |
Stakeholder Opinions: Diabetic Renal DiseaseWhat are the current definitions, pathophysiological stages and the natural history of progression of diabetic renal disease? / / |
2008 | 3.800,00$ |
RNA therapy: the next big thing after monoclonal antibodies?Strategic review of the different RNA therapy technology offerings / / Assessment of the commercial potential of key products / |
2008 | 7.600,00$ |
Sepracor Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompa |
2008 | 5.700,00$ |
M&A trends in PharmaOverview of the main trends driving M&A activity / / Analysis of key transactions in the past and the current state of the ne |
2008 | 11.400,00$ |
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growthDescription of the competitive landscape in antidyslipidemics market with detailed overview of main challenges for launched and no |
2008 | 15.200,00$ |
Biogen Idec Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector. The profile enco |
2008 | 5.700,00$ |
Solvay S.A.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
Les Laboratoires Servier: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile |
2008 | 5.700,00$ |
Merck KGaA: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encom |
2008 | 5.700,00$ |
Stakeholder Insight: Osteoporosis - Generic alendronate further establishes oral bisphosphonates as gold standardPatient segmentation by disease severity as defined by the WHO; including osteopenia, osteoporosis, and severe/established osteopo |
2008 | 15.200,00$ |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare August 2008 (analysis of merger and acquisition (M&A), private equity, venture financing, private placement, initial public offering (IPO), and secondary offering deals)Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth anal |
2008 | 495,00$ |
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkageThe antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of t |
2008 | 15.200,00$ |
Sales Force EffectivenessProvides an overview of the current drivers behind the evolution of sales force effectiveness / / Analyzes current and emerging s |
2008 | 7.600,00$ |
Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversityAn overview of the current trends in pharmaceutical portfolio management / / Analysis of the ways in which pharmaceutical compani |
2008 | 3.800,00$ |
Trends in Clinical Trials: Strategies to enhance clinical trial designOverview of current clinical trial trends / / Strategic recommendations on how to optimize clinical trial success / / Case study |
2008 | 3.800,00$ |
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor typesExamination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor type |
2008 | 11.400,00$ |
F. Hoffmann-La Roche Ltd.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile en |
2008 | 5.700,00$ |
Nycomed A/S: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile |
2008 | 5.700,00$ |
Genzyme Corporation: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile |
2008 | 5.700,00$ |
Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis, |
2008 | 495,00$ |
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis, |
2008 | 495,00$ |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscapeCompany-by-company evaluation of all Big Pharma-led M&A permutations within the PharmaVitae Rx pharma universe / / Evaluation of |
2008 | 7.600,00$ |
GlaxoSmithKline plc: PharmaVitae ProfileThis analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompass |
2008 | 5.700,00$ |
Eli Lilly & Co.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompas |
2008 | 5.700,00$ |
Boehringer Ingelheim GmbH: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profi |
2008 | 5.700,00$ |
Chugai Pharmaceutical Co. Ltd: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile e |
2008 | 5.700,00$ |
Genentech Inc.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompas |
2008 | 5.700,00$ |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare June 2008 (analysis of monthly deal activity along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial publInsights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis |
2008 | 495,00$ |
Bristol-Myers Squibb Co.: PharmaVitae ProfileThis analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompass |
2008 | 5.700,00$ |
Novo Nordisk A/S: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile |
2008 | 5.700,00$ |
Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenuesNeurological conditions covered: Alzheimer's disease, Parkinson's disease, MS, epilepsy, migraine, insomnia, Huntington's disease |
2008 | 3.800,00$ |
Schering-Plough Corporation: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encom |
2008 | 5.700,00$ |
Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapiesAnalysis of the current unmet needs in cardiovascular disease markets / / Opinion leader commentary on key clinical trials and ma |
2008 | 7.600,00$ |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities aheadAssessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compounds / / R |
2008 | 15.200,00$ |
Johnson & Johnson: PharmaVitae ProfileThis analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompass |
2008 | 5.700,00$ |
Wyeth: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile en |
2008 | 5.700,00$ |
Bayer Schering Pharma AG: PharmaVitae ProfileThis analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile |
2008 | 5.700,00$ |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare (analysis of monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial public offeriInsights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis |
2008 | 495,00$ |
Zimmer Holdings Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Varian Medical Systems Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
CSL Limited: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Micromet Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Optimer Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Javelin Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Spectrum Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Nuvelo Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Incyte Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Stryker Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Panacos Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
La Jolla Pharmaceutical Co: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Lexicon Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
KV Pharmaceutical Company: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Avigen Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
C.R. Bard Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Danaher Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Medtronic Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Smith & Nephew plc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Transition Therapeutics Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
TorreyPines Therapeutics Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
St. Jude Medical Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Novacea Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Illumina Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
LifeCell Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
MannKind Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Cytori Therapeutics Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Cougar Biotechnology Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
MorphoSys AG: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Lev Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Introgen Therapeutics Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Theratechnologies Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Poniard Pharmaceuticals Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Becton, Dickinson and Co: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Allos Therapeutics Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Antisoma plc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Beckman Coulter Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
BIOMS Medical Corp: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Anesiva Inc: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Boston Scientific Corporation: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
Carl Zeiss Meditec AG: Premium Company ProfileContains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye |
2008 | 495,00$ |
ZIOPHARM Oncology Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis, |
2008 | 495,00$ |
Watson Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Vital Signs Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Vernalis plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Trinity Biotech Plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
TomoTherapy Incorporated: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Titan Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
The Medicines Company: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Telik Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Targanta Therapeutics Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
SenoRx Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Sangamo BioSciences Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Qiagen NV: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Protherics PLC: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Orexigen Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
NuVasive Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Noven Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Natus Medical Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Metabasis Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Medivation Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Jazz Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Iomai Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Intuitive Surgical Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Hologic Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Halozyme Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Geron Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Genomic Health Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Genaera Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Flamel Technologies SA: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Favrille Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Edwards Lifesciences Corp: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Dendreon Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Chelsea Therapeutics International Ltd: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Candela Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Cadence Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
BTG plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Biovail Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Bionovo Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
BioMimetic Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Basilea Pharmaceutica: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
AVANT Immunotherapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
AspenBio Pharma Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
ARYx Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
AngioDynamics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Anadys Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
ADVENTRX Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Advanced Medical Optics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Accentia Biopharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company ProfileContains corporate strategy, value chain presence and SWOT Analysis
/
/ Provides detailed business description, segment analysi |
2008 | 495,00$ |
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demandOverview of menopause, including a review of the prevalence of vasomotor symptoms to better understand the size of the target pati |
2008 | 3.800,00$ |
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major playersAnalysis of patient potential, unmet needs and clinical trial design in the neuropathic pain market. / / Overview of key marketed |
2008 | 15.200,00$ |
Monoclonal Antibodies Report: 2008 UpdateComprehensive financial strategic analysis of the mAb market out to 2013 / / Global sales forecasts to 2013 for marketed and Phas |
2008 | 7.600,00$ |
Online patient recruitment and its impact on patient relationship managementOverview of the benefits and drawbacks of online recruitment Analysis of the online patient recruitment process Analysis of the ke |
2008 | 3.800,00$ |
Forecast Insight: Osteoarthritis -Scope
/
/ This report gives a strategic analysis of the likely impact that recent events will have on the osteoarthritis market |
2008 | 15.200,00$ |
Drug Repositioning Strategies - Serendipity by designScope / An outline of what drug repositioning is, and what is driving it. / / An overview of the key players in the repositioning |
2008 | 3.800,00$ |
Stakeholder Opinions: Biologics in Infectious Diseases Well defined target populations are key to commercial successAn overview of the past, current and emerging technologies for biologics as well as obstacles faced in development. Discussion of |
2008 | 3.800,00$ |
Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain managementAn overview of the drug supply chain in Europe and the US. Identification of the key players in the drug supply chain. Coverage of |
2008 | 3.800,00$ |
Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapiesAssessment of patient size across the seven major and additional emerging markets, including split by sex and race where available |
2008 | 3.800,00$ |
Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agentsOverview of bone metastases epidemiology, which is currently unknown, disease mechanisms, complications and diagnosis Current trea |
2008 | 3.800,00$ |
eHealthInsight Series: Reaching Doctors and Patients Through New Digital MediaOverview of the current challenges facing existing sales and marketing models. A review of online activities of physicians and pat |
2008 | 3.800,00$ |
Using a Multi-faceted Approach to Increasing EHR Adoption (Strategy Focus)Identifies opportunities in the global EHR market Analyzes approaches to EHR adoption Offers insight into EHR technology trends / |
2008 | 1.895,00$ |
Wealth Management in Japan 2007Presents data from Datamonitor's Global Wealth model on the number of wealthy individuals and their aggregate onshore liquid asset |
2007 | 4.495,00$ |
Wealth Management in Australia 2007Presents data from Datamonitor's Global Wealth model on the number of wealthy individuals and their aggregate onshore liquid asset |
2007 | 4.495,00$ |
Formulating an effective CRM strategy (Strategy Focus)Pharmaceutical companies need to increase drugs' profitability during its profit window A reduced sales force needs to be more |
2007 | 1.895,00$ |
M&A, Partnerships and Organic Growth in Wealth Management, Q2 2007Extensive research is conducted on the activities of 50 providers of wealth management products, globally The developments are ana |
2007 | 1.695,00$ |
Product Innovation and Customer Targeting in Wealth Management, Q2 2007Extensive research is conducted on the activities of 50 providers of wealth management products, globally The developments are ana |
2007 | 1.695,00$ |
Staffing in Wealth Management, Q2 2007Follows the staffing-related activities of 57 leading international wealth managers Covers wealth managers with operations worldwi |
2007 | 1.695,00$ |
Future Spending of CRM Technologies, Europe, 2006-2012 (Databook)Includes segmentations for software and services in the CRM market for the Pharmaceutical industry. Projects the growth for the ma |
2007 | 1.295,00$ |
Future Spending of CRM Technologies, North America and Japan, 2006-2012 (Databook)Includes segmentations for software and services in the CRM market for the Pharmaceutical industry. Projects the growth for the ma |
2007 | 1.895,00$ |
Global Pharmaceutical IT Spending Forecast through 2013 (Interactive Model)Understand the opportunity size for technology spending in the global life science market
/ Identify potential areas for spending |
2008 | 15.000,00$ |


